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Abstract: The majority of cancer deaths occur because of metastasis since current therapies are largely
non-curative in the metastatic setting. The use of in vivo preclinical mouse models for assessing
metastasis is, therefore, critical for developing effective new cancer biomarkers and therapies.
Although a number of quantitative tools have been previously developed to study in vivo metastasis,
the detection and quantification of rare metastatic events has remained challenging. This review
will discuss the use of circulating tumor cell (CTC) analysis as an effective means of tracking and
characterizing metastatic disease progression in preclinical mouse models of breast and prostate
cancer and the resulting lessons learned about CTC and metastasis biology. We will also discuss how
the use of clinically-relevant CTC technologies such as the CellSearch® and Parsortix™ platforms for
preclinical CTC studies can serve to enhance the study of cancer biology, new biomarkers, and novel
therapies from the bench to the bedside.
Keywords: circulating tumor cells; preclinical models; metastasis
1. Introduction
Cancer is currently one of the leading causes of death worldwide with the projected number of
cases expected to increase 50% from 2012 to 2030 [1]. The five-year survival rates for non-metastatic
prostate and breast cancers in the United States range from 93% to 100% [2,3]. However, as these
cancers progress, cells may escape from the primary tumor and spread to distant organs in the body,
through a deadly process called metastasis [4]. Approximately 90% of cancer-related deaths occur as a
result of metastasis [5]. Correspondingly, five-year survival rates for metastatic prostate and breast
cancer drop to approximately 29% and 22%, respectively [2,3]. Recurrence is also seen in 30% to 40%
of patients after successful treatment of a primary tumor, of which 50% is a recurrence of metastatic
disease [4,6].
Current therapies are non-curative towards these aggressive cancers. Therefore, more research
is required to successfully identify and treat patients with metastatic cancer. In particular, the use
of in vivo preclinical animal models of metastasis provide an important opportunity to study and
develop novel biomarkers such as circulating tumor cells (CTCs) in controlled experimental studies,
which, in turn, may also provide information for developing new clinical treatments targeted against
metastatic disease. This review will provide a brief overview of the metastatic process and how it
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is detected clinically including the use of imaging and CTC assays. We will then highlight different
approaches for modeling and tracking metastatic progression in vivo in the preclinical setting with
a particular focus on CTC generation and CTC assays that can be implemented for the preclinical
development and/or optimization of new metastasis biomarkers.
2. The Metastatic Process
Metastasis is the spread of cancer from the primary tumor to a secondary location within the
body [7] and different types of cancer have specific affinities for certain target organs, which support
growth of secondary tumors [8]. The multi-step process of metastasis is complex (see Figure 1)
and begins with the local infiltration of cancer cells out of the primary tumor into the surrounding
vasculature [9]. Angiogenesis, the growth of a vascular network formed from pre-existing vessels, is an
important step in facilitating tumor cell escape from the primary tumor [9,10]. Once in the bloodstream,
cancer cells must survive physical shear stress and/or immune challenge in the circulation in order
to disseminate throughout the body [9]. These cells often arrest in capillary beds of distant organs
and can then extravasate out of the bloodstream into the secondary organ. Here they may die, remain
dormant, or proliferate in order to colonize a metastatic tumor at a secondary location [9]. According
to the seed and soil hypothesis [8], each cancer type has a specific pattern of metastasis called organ
tropism. For example, when considering the four most common types of cancer [11], lung cancer
will metastasize to the brain, bones, and adrenal glands [12] while breast cancer will metastasize
to bones, lungs, the liver, and the brain [13]. Prostate cancer metastasizes to bones, lungs, the liver,
the brain, and lymph nodes [14,15] and colorectal cancer metastasizes to the lungs, the liver, and the
peritoneum [16].
Diagnostics 2018, 8, x FOR PEER REVIEW  2 of 20 
 
how it is detected clinically including the use of imaging and CTC assays. We will then highlight 
different approaches for modeling and tracking metastatic progression in vivo in the preclinical 
setting with a particular focus on CTC generation and CTC assays that can be implemented for the 
preclinical development and/or optimization of new metastasis biomarkers. 
2. The Metastatic Process 
Metastasis is the spread of cancer from the primary tumor to a secondary location within the 
body [7] and different types of cancer have specific affinities for certain target organs, which support 
growth of secondary tumors [8]. The multi-step process of metastasis is complex (see Figure 1) and 
begins with the local infiltration of cancer cells out of the primary tumor into the surrounding 
vasculature [9]. Angiogenesis, the growth of a vascular network formed from pre-existing vessels, is 
an important step in facilitating tumor cell escape from the primary tumor [9,10]. Once in the 
bloodstream, cancer cells must survive physical shear stress and/or immune challenge in the 
circulation in order to disseminat  throughout the b dy [9]. These cells ofte  arr st in capill ry beds 
of distant organs nd can th n extravasat  out of the bloodstream into the secondary rgan. Here 
they may die, remain dormant, or proliferate in order to colonize a metastatic tu or at a secondary 
location [9]. According to the seed and soil hypothesis [8], each cancer type has a specific pattern of 
metastasis called organ tropism. For example, when considering the four most common types of 
cancer [11], lung cancer will metastasize to the brain, bones, and adrenal glands [12] while breast 
cancer will metastasize to bones, lungs, the liver, and the brain [13]. Prostate cancer metastasizes to 
bones, lungs, the liver, the brain, and lymph nodes [14,15] and colorectal cancer metastasizes to the 
lungs, the liver, and the peritoneum [16]. 
 
Figure 1. The metastatic process. The multistep process of metastasis is complex and includes 
primary tumor vascularization, escape/intravasation of tumor cells into the bloodstream, survival in 
the bloodstream, and dissemination throughout the body, extravasation out of the bloodstream, and 
secondary tumor formation in distant organs. 
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Figure 1. The metastatic process. The multistep process of metastasis is complex and includes
primary tumor vascularization, escape/intravasation of tumor cells into the bloodstream, survival
in the bloodstream, and dissemination throughout the body, extravasation out of the bloodstream,
and secondary tumor formation in distant organs.
3. Clinical Imaging Techniques for Identifying and Tracking Metastasis
In order to develop th rapies aimed at tre ting metastasis, clinic l imaging technologies must be
able to sensitively detect and monitor metastasis. While there are a wide range of approaches available
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to assess disease progression in patients, only a few emerge as reliable and commonly performed.
Each have their own advantages and disadvantages.
3.1. Whole Body-Bone Scanning
Detection of bone metastases has traditionally been accomplished using whole body-bone
scanning (WBS) or scintigraphy [6]. These scans are typically 15–20 min in duration during which
a patient will lie inside the imaging instrument, which rotates around the patient transmitting
radiation to take X-ray-like images [17]. WBS can be used with magnetic resonance imaging (MRI),
positron emission tomography (PET), and/or computed tomography (CT) technologies to obtain the
whole-body images (described further below) [18]. Studies have shown that up to 80% of prostate
cancers, 70% of breast cancers, and 15% to 30% of lung, colon, stomach, bladder, uterus, rectum, thyroid,
or kidney cancers will metastasize to the bone [19–21]. This metastasis imaging technique is mainly
reserved for patients with high-risk cancers rather than for lower-risk cancer patients who are unlikely
to have metastasis [22]. WBS provides detection of whole-body bone metastasis at low cost and is
readily available [6]. However, WBS has low specificity for detecting bone metastasis with reported
inadequate sensitivities in 70% to 90% of patients resulting in false-positive bone scans due to the
inability of distinguishing between metastasis and other pathological conditions [23]. Consequently,
WBS (as a sole imaging technique) is considered imprecise for diagnosing cancer metastasis [6].
3.2. Single Photon Emission Computed Tomography
Single photon emission computed tomography (SPECT) is another imaging technique commonly
used to assess bone metastasis in cancer patients [24] as well as liver, lung, and lymph node
metastasis [25,26]. SPECT takes two-dimensional images from single or multiple views to estimate
three-dimensional radioactivity distribution inside a patient [22,27]. SPECT has higher diagnostic
accuracy compared to WBS when used to detect bone malignancies and is able to be directly compared
to other tomography-based techniques including the MRI [28]. However, SPECT has its own set of
challenges with regards to image reconstruction [27]. The amount of radiopharmaceutical that can be
administered is also limited by the maximum allowable dose of radiation to the patient, which results
in a limited number of photons that can be used for imaging [27]. Collimator limitations can also
decrease the photons available for imaging and can be associated with a loss of spatial resolution [27].
Lastly, since non-specific uptake in nonmalignant bone lesions may negatively impact the accuracy of
bone scans using SPECT, it is common to use further examination techniques such as CT imaging or
MRI in conjunction with SPECT when assessing a patient for metastatic disease [28].
3.3. Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) uses a magnetic field to produce detailed images of cancer
in patients [29]. These images can be used to assess localization for staging and to evaluate tumor
aggressiveness along with providing guidance for patient treatment [30]. MRI uses non-radioactive
contrast media and has better sensitivity and specificity for detecting metastasis compared to SPECT
and WBS [23,31]. MRI is also commonly used to assess brain metastasis [32] as well as lesions in the
liver and lymph nodes [33]. Unlike WBS and SPECT, MRI is increasingly performed in low-risk and
intermediate-risk cancer patients as part of surveillance for metastasis and to determine eligibility
for biopsies in less aggressive cancers such as prostate cancer [30]. However, in many cases, MRI can
produce false-positive results by detecting non-specific bone lesions, which are of unknown clinical
significance [30]. Importantly, because of the magnetic nature of MRI, patients who have metal implants
in their body (such as cochlear implants, clips for brain aneurysms, coils in blood vessels, pacemakers,
and more) are unable to have an MRI scan due to the possibility of damaging or dislodging the metal
devices [34]. This limits the patient population and may exclude many patients who would benefit
from MRI imaging to assess cancer metastasis.
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3.4. Positron Emission Tomography and Computed Tomography
Positron emission tomography (PET) uses radiotracers to evaluate changes in organ and tissue
functions at a cellular level [35]. PET has the ability to detect the onset of disease earlier than many
other imaging techniques. However, multiple studies have reported such a large selection of PET
tracers that it becomes difficult to designate which tracer is best since each has unique advantages
and disadvantages [6,22,23,36]. For example, in prostate cancer patients, fluoro-D-glucose PET
has been shown to lack sensitivity while fluoride PET lacks specificity. While prostate-specific
membrane antigen-targeted PET shows promise, this tracer lacks evidence from clinical trials
evaluating the role of clinical parameters such as androgen-sensitivity versus castrate-resistance [36].
Other available PET tracers include 11C-labeled or 18F-labeled choline and acetate, 11C-methionine,
18F-fluorodihydrotes-testosterone, and 18F-Fluoride [37]. However, an emerging theme in the extensive
research comparing PET techniques is the combination of PET and computed tomography (CT) to
enhance metastasis detection in patients [22,23,36]. PET/CT can take advantage of specific PET
properties such as high sensitivity (depending on which tracer is used) and can reduce the risk of
false-positives by using CT data to confirm the morphology of scintigraphic lesions [38]. PET/CT
imaging can be used to assess a large variety of metastatic sites including lymph nodes, lungs, bones,
and liver [39–42].
Despite advances in clinical imaging technologies, challenges remain for accurate detection
and tracking of metastasis in cancer patients, particularly at earlier stages of the metastatic process.
Available imaging approaches are often limited to detecting more advanced metastatic tumors because
of issues with sensitivity and specificity, particularly if the location of metastasis is not known. The cost
of instrumentation [43,44] and experienced clinical radiology personnel can also be a limitation
particularly for smaller or remote hospitals. In the preclinical laboratory setting, imaging of metastasis
in animal models is also challenged by the high costs associated with sophisticated imaging equipment
including instruments for assessing fluorescence/luminescence as well as clinically-relevant imaging
such as WBS, MRI, and PET/CT. In addition, it is also necessary for labs to employ experienced
technicians to carry out the imaging and interpret the results. Therefore, large imaging equipment is
often not a feasible option for preclinical laboratories with modest operating budgets. An emerging
alternative approach which may help address these challenges in both the clinical and preclinical
settings involves blood-based detection and tracking of metastatic disease including assays for analysis
of circulating tumor cells (CTCs) [45].
4. Circulating Tumor Cell Analysis Approaches
Circulating tumor cells (CTCs) are cancer cells that have escaped from the primary tumor and are
disseminated throughout the body via the blood circulation as part of the metastatic process [46,47].
CTCs present a unique opportunity to analyze rare/early metastatic events and metastatic progression
by capturing and characterizing cells collected from patient blood samples [45,47]. CTCs can provide
important insight into a patient’s individual disease and offer an opportunity for single or rare
cell analyses in the form of a minimally-invasive, real-time “liquid-biopsy” for monitoring disease
progression and treatment responses [48,49]. The presence of CTCs has been associated with poor
prognosis and treatment responses in the clinical setting [50] and CTCs can also be used as predictive
markers to increase treatment efficacy [51]. This could eventually reduce healthcare costs and be a
valuable tool for personalized treatment [52–54].
In metastatic cancer patients, the frequency of CTCs is approximately 1 CTC per 106 leukocytes
and, therefore, extremely sensitive and reproducible technologies are needed to analyze these cells in
patient blood samples [45,47]. Because of the rare nature of CTCs, most assays use a combination of
enrichment and detection/characterization techniques, which are described below and in Figure 2.
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Figure 2. Overview of circulating tumor cell enrichment techniques. (A) Density-based CTC
enrichment combines whole blood with density-gradient media such as Ficoll to separate based
on cell density. Mononucleated cells including CTCs can then be recovered for further analysis;
(B) Size-based CTC enrich ent allows the smaller blood cells to pass through size restricted pores
or channels whil larger tum c lls are captured; (C) Immunomag etic-based CTC enrichment
either selects positively (for TCs) or negativ ly (for white blood cells) using iron-labeled target
antibodies; (D) Microfluidic-based CTC enrichment passes blood through either chip-based devices
and/or antibody-coated micro-posts (depicted) to enrich CTCs from whole blood.
4.1. CTC Enrichment Techniques
4.1.1. D nsity-Based Enrichment
Density-based isolation of CTCs takes advantage of the differences in density between CTCs
(<1.077 g/mL) and blood cells (>1.077 g/mL) [55]. Ficoll-Paque® (Sigma-Aldrich, St. Louis, MO,
USA), OncoQuick® (Greiner Bio-One, Monroe, NC, USA), and RosetteSep™ (StemCell Technologies,
Vancouver, BC, USA) are all technologies that use density-based differences to separate CTCs from the
blood. These approaches use density gradient medium to collect mononuclear cells (including CTCs)
from blood samples (see Figure 2A) [56]. Similar to size-based enrichment techniques, collecting
CTCs by density gradient allows for capture of both epithelial and mesenchymal CTCs and these
techniques are also relatively easy and inexpensive to perform [55]. However, some shortcomings of
density-based techniques include low specificity (because of the lack of specific selection for CTCs
within the mononuclear fraction) combined with the opportunity for cross-contamination of CTCs
with other cell types in the blood due to migration of cells to the plasma layer or due to the presence of
clotting/aggregates [55].
4.1.2. Size-Based Enrichment
Sized-based isolation of CTC capitalizes on the differences in size between CTCs (>8 µm)
compared to leukocytes (<8 µm) [56,57]. Parsortix™ (Angle PLC; Surrey, UK), ScreenCell® (Westford,
MA, USA), and ISET® (Rarecells, Paris, France) are examples of CTC technologies that use size-based
techniques in conjunction with other methods to isolate the CTCs from blood samples. Typically,
whole blood is passed through a filtration device with different pores or channels (usually 6–10 µm)
or different filter-based approaches with the common goal of allowing isolation of CTCs from other
blood components and retrieval of CTCs for further experimentation including multiplexed imaging,
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genetic analysis, or culturing (see Figure 2B) [56–58]. The advantages of size-based enrichment
techniques include the straightforward and relatively inexpensive nature of these assays as well as
the ability to identify both epithelial and mesenchymal CTCs [55]. However, size-based assays can be
prone to clogging within the pores/channels and the low specificity of these assays sometimes causes
small CTCs to be lost during the enrichment process [55].
4.1.3. Immunomagnetic-Based Enrichment
The most widely used CTC enrichment/isolation technique is immunomagnetic-based selection
of CTCs [58]. Immunomagnetic separation uses magnetic, bead-based separation technology [55].
CTCs are enriched from blood samples using antibodies conjugated to magnetic beads, which are
designed to either positively select for CTCs by targeting various epithelial or tumor-specific antigens
expressed by tumor cells or negatively select for CTCs by targeting contaminating blood cell
antigens such as CD45 (see Figure 2C) [55,56]. AdnaTest (QIAGEN Hannover GmbH, Langenhagen,
Germany), MACS® (Miltenyi Biotec, Auburn, CA, USA), IsoFlux™ (Fluxion Biosciences, Alameda,
CA, USA), and the CellSearch® system (Menarini Silicon Biosystems Inc, San Diego, CA, USA) all use
immunomagnetic approaches for CTC enrichment [55]. The various immunomagnetic technologies
have different advantages. For example, MACS maintains cell integrity while AdnaTest uses defined
markers and allows for downstream analysis of CTCs with the possibility of characterization of
epithelial/mesenchymal phenotype. Through customizable IgG beads, Isoflux allows users to mix
the antibodies of their choice when enumerating CTCs, which allows for very high customization.
Lastly, the CellSearch® is a regulatory-approved (United States Food and Drug Administration (FDA)),
semi-automated technology that uses positive CTC enrichment via EpCAM (epithelial cell adhesion
molecule) combined with image analysis. However, each of these technologies also has drawbacks
including false positive/false negative isolation of CTCs (MACS®, AdnaTest) and limited flexibility
in assay design or marker choice (AdnaTest, CellSearch®). In addition, the CellSearch® only allows
for capture of epithelial CTCs and has very limited capacity for downstream analysis of CTCs once
they are identified. The greatest limitation with regards to immunomagnetic separation of CTCs from
blood samples is the lack of a reliable “universal marker” that can be used independently of both the
tumor type and the stage of disease progression [55].
4.1.4. Microfluidic-Based Enrichment
To enrich for CTCs using microfluidic-based techniques, whole blood is passed through µm-sized
channels by using chip-based devices designed with micro-channels etched or molded into surfaces
such as glass, silicon, or polymers [56]. CTCs can then be captured by antibody-coated microposts
or by size/deformability (see Figure 2D) [56]. Parsortix™, CTC-Chip/iChip, IsoFlux™, and GILUPI
CellCollector™ (NanoMedizin, Potsdam, Germany) are all techniques that use microfluidics as a
basis to enrich for and capture CTCs. Microfluidic-based techniques generally have high enrichment
percentages and allow for the release of intact CTCs after enrichment to facilitate downstream analysis.
However, similar to immunomagnetic enrichment techniques, these assays lack a “universal marker”
targeting all cancer subtypes including cancers of advanced metastatic disease.
4.2. CTC Detection/Characterization Techniques
Once CTCs have been enriched from the blood, detection, enumeration, and/or molecular
characterization can be carried out using a variety of protein-based and nucleic acid-based approaches,
which are summarized in Table 1 [55].
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Table 1. Comparison of protein-based and nucleic acid-based approaches for circulating tumor cell
characterization in patient samples.
Type Approach Sample VolumeRequirement *
Ability for CTC
Quantification
High
Specificity
High
Sensitivity
Labor-Intensive/
Challenging
Down-Stream
Analysis
Protein-Based
Immunofluorescence Small Yes Yes No Yes Yes
Flow Cytometry Medium Yes Yes No Yes Yes
CellSearch® Large Yes Yes Yes No No
CTC-Chip/iChip Large Yes Yes Yes Yes Yes
AdnaTest Large No Yes Yes No No
Isoflux Large Yes Yes Yes No Yes
Nucleic
Acid-Based
RT-PCR Small No No Yes No No
qRT-PCR Small No No Yes No No
Next-Gen
Sequencing Small No Yes Yes Yes Yes
* Small: ≥100 µL, Medium: ≥1 mL, Large: ≥7 mL.
4.2.1. Protein-Based Detection and Characterization
Protein-based detection and characterization of CTCs can be carried out using different techniques
such as slide-based immunofluorescence, flow cytometry, CellSearch®, and the CTC-Chip/iChip [57].
Typically this is done through the use of fluorescent-conjugated antibodies targeting epithelial
antigens such as CK-19 and EpCAM on CTCs and identification through laser-based and/or
image-based detection systems [56,57]. These approaches allow for analysis of large sample
volumes with high specificity [55]. However, some image-based characterization techniques such
as manual microscopy-based immunofluorescence analysis of stained CTCs can be very slow and
labor-intensive while other methods such as flow cytometry have low sensitivity and can be technically
challenging [55–57].
4.2.2. Nucleic Acid-Based Detection and Characterization
Frequently used nucleic acid-based detection and characterization of CTCs include real-time (RT)
and quantitative RT (qRT) polymerase chain reaction (PCR) to identify CTCs based on expression of
specific genes of interest [57]. In addition, more sophisticated methods such as next-generation
sequencing and genomic analysis (including at the single-cell level) are emerging as valuable
(albeit technologically challenging) tools for detailed CTC characterization since it relates to disease
characteristics. The high sensitivity of nucleic acid-based techniques allows for analysis of a small
number of CTCs although the amplification bias of PCR can lead to false-positive results and/or low
specificity of CTC detection [57]. In addition, these approaches cannot accurately quantify/enumerate
the number of CTCs in a sample, don’t allow for visualization of CTCs, and do not allow for recovery
and further analysis of CTCs [55].
4.3. Additional CTC Analysis Approaches
4.3.1. Dielectrophoresis
Approaches such as DEPArray™ (Silicon Biosystems, Bologna, Italy) involve an
electrophoretic-based cell-sorting and isolation platform for single-cell purification and analysis
of live or fixed cells. DEPArray™ digitally sorts 100% pure subpopulations of cells from samples
using a chip-based microfluidic cartridge and automated microscope image-based analysis [59,60].
This system does require that cells are already enriched from whole blood samples using one of
the techniques described above [49]. Labeled cells are loaded into the DEPArray™ cartridge where
electrodes are activated to form DEP cages by trapping the labeled cells. The cartridge is scanned in
each desired fluorescence channel to identify target cells, which are moved into a designated area.
Individual cells are then dispensed into a collection tube for further analysis with Silicon Biosystems
CellBrowser™ software [59,60]. This allows for differential analysis and characterization of tumor cell
populations using next-generation sequencing [61]. The DEPArray™ is best suited for small sample
sizes (<10,000 cells) and is ideal for further molecular characterization of small pure CTC samples.
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With samples containing more than 10,000 cells, the assay may have reduced ability for single-cell
purity/resolution [49,59,60].
4.3.2. Direct Cellular Imaging
The Epic Sciences platform (San Diego, CA, USA) was designed for detection and molecular
characterization of CTCs in whole blood regardless of the epithelial status and without an enrichment
step [62]. To enumerate cells for protein biomarker analysis, the EPIC Sciences platform first
consists of slide prep where whole blood is lysed and nucleated cells are deposited onto slides
and frozen [62,63]. Slides are then immunofluorescently stained and scanned by using Epic’s rapid
scanning method [62,63]. By assessing protein expression and morphology, Epic can differentiate
between white blood cells and CTCs, which can then be characterized into different subsets including
“traditional” CTCs (CK-positive), CTC clusters, CK-negative CTCs, and apoptotic CTCs or can be
characterized by a custom-selected set of markers [62,63]. Studies have shown that the Epic Sciences
platform has high cell recovery, high specificity, and high reproducibility for CTC detection and
characterization [62].
Overall, there are a number of promising technologies being developed for tracking and
characterizing metastasis and treatment response using CTCs. However, several challenges remain
and further work is needed to understand the biology of CTCs in the context of metastatic progression
in order to optimize their wide-spread use as clinical biomarkers. In order to do this, analysis of
CTCs using in vivo preclinical animal models of metastasis provides an important opportunity to
study CTCs and to develop and/or optimize CTC assays in controlled experimental metastasis studies.
The remainder of this review will describe different approaches that can be used to study metastatic
progression and CTCs in the preclinical setting, including details of each of the various available CTC
assays and a summary of the current advances and challenges of preclinical CTC analysis.
5. Preclinical Models of Metastasis and CTC Generation
The presence of CTCs in the blood has been correlated with disease progression towards
metastasis [45]. Therefore, in order to study CTCs in a preclinical setting, we must generate metastatic
disease using in vivo animal models such as mice. There are many different preclinical mouse models
of metastasis. Each has specific advantages and disadvantages, which largely differ in many facets
including time to metastasis development, experimental costs, and patient specificity.
5.1. Spontaneous Metastasis Models
Preclinical in vivo models for spontaneous metastasis involve injection of cancer cells into their
orthotopic site of origin [64,65]. For example, the correct orthotopic injection site for breast cancer
cells is the mammary fat pad of female mice, while prostate cancer cells are injected into the prostate
gland of male mice followed by monitoring of disease progression over time [64,65]. The advantage of
spontaneous metastasis models is the ability to model and analyze all steps of disease progression
including the growth of the primary tumor and eventual spontaneous metastasis to distant organs [64].
This allows for natural development and monitoring of cancer metastasis as it progresses in a biological
setting. Therefore, this is a better approach to modelling the full spectrum of clinical disease compared
to intravenous models (described below) [65]. However, natural disease progression in spontaneous
metastasis models often takes a long time and primary tumor burden may become too great for the
animal before metastasis can spontaneously occur. Therefore, depending on the aggressiveness of
the orthotopically injected cells, there is no guarantee that metastasis will occur before the host is
overcome by disease burden. To combat this, an alternative approach involves surgical removal of the
primary tumor to allow for metastases to progress to a detectable size [66].
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5.2. Experimental Metastasis Models
Experimental metastasis models involve injecting tumor cells directly into the blood circulation
of the animal [66]. Using these models, tumor cells can be targeted for delivery to, and metastatic
growth in, different organs depending on the route of the injection [64]. For example, tail vein injection
targets cells towards the lung while the mesenteric vein targets cells towards the liver. Intra-cardiac
injection is aimed, but is not precise, at targeting metastatic growth in the bone and/or brain [64].
Using this approach, tumor cells bypass the initial steps of primary tumor growth and intravasation,
which reduces the time to metastasis and secondary tumor formation [64,66]. However, although
injecting cells into the vasculature can result in a wide distribution of tumor cells throughout the
body, the largest number of cells interacting with tissues will be located at the site of the first capillary
bed encountered [66]. Other criticisms of the experimental metastasis model arise from the limited
sensitivity of the assay based on the inability to precisely target the site of metastasis. [64]. Furthermore,
bypassing the biological mechanisms of primary tumor growth and intravasation of cells may not fully
represent metastasis in the clinical setting [66].
5.3. Genetically Engineered Mouse Metastasis Models
Genetically engineered mouse models (GEMMs) manipulate target oncogene or tumor suppressor
expression in mice in order to promote tumor development [67]. Transgenic and knockout GEMMs
have provided important models for identifying tumor-associated and metastasis-associated genes
that can lead to tumor formation and disease progression [67,68]. However, since genetic mutations
in GEMMs are simultaneously modified in all cells of the animal or in the targeted organ/tissue,
these models do not accurately represent the natural progression of sporadic cancer events resulting
from accumulated genetic events in single cells [67,68]. Cre-ERT, Cre-loxP, and Flp-FRT/Cre-loxP
recombination systems have been applied in an attempt to mimic the accumulation of mutations in
multistep carcinogenesis, but are still imperfect at emulating biological cancer progression [67,68].
Evaluating metastasis preclinically in GEMMs remains challenging. However, one approach that
has been used to address this is orthotopic transplantation of GEMM-derived tumor fragments into
secondary murine hosts, which has been shown to generate metastasis [67,68]. Similar to techniques
used in spontaneous mouse models, implantation can be followed by surgical resection of the primary
tumor to allow time for the development of metastatic disease. While there is much to be learned from
GEMMs, these metastasis models remain time-consuming, laborious, and quite expensive [67].
5.4. Patient-Derived Xenograft Models of Metastasis
Patient-derived xenograft (PDX) models may circumvent many potential artifacts seen in other
metastasis models. PDX mice are created by orthotopic or subcutaneous implantation of fresh human
tumor samples into immunodeficient mice rather than using cultured cell lines [68]. The PDX
model system is currently the only method that incorporates the inter-patient and intra-tumor
heterogeneity that is present in human cancer by growing patients’ own tumor samples directly
in mice [68]. This allows for a highly personalized study of tumor progression and treatment responses.
Furthermore, PDX models have been shown to provide a continuous and renewable source of human
CTCs [69]. A significant correlation has been shown between the presence of CTCs in early breast cancer
patients and in mice. Therefore, these types of models may be used to evaluate in early metastatic
events [69]. However, PDX models are not without limitations, which include high variability in
engraftment rates based on tumor type and grade, time to metastasis progression, and the need
for direct access to fresh clinical specimens for initial implantation [68]. Similar to other in vivo
preclinical metastasis models involving injection of human cancer cells or tissues, the requirement
for immunocompromised host mice reduces or eliminates the ability to study immune cell function
and analyze immunotherapeutic strategies [68]. Lastly, similar to GEMMs, PDX mice are extremely
time-consuming, labor-intensive, and costly.
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6. Tracking Metastasis and CTCs in Preclinical Models
6.1. Technologies for Preclinical Evaluation of CTCs
In the preclinical setting, multiple CTC enumeration technologies are becoming available for use in
tracking metastasis, developing biomarkers, and assessing molecular analysis of CTCs. These include
a number of new emerging technologies that have been shown to process the small volumes of blood
obtained from preclinical models such as the VTX-1 platform (Vortex Biosciences, Menlo Park, CA,
USA) [70] and the ApoStream technology (ApoCell, Houston, TX, USA) [71]. Our research group has
demonstrated the value of using three different technologies for CTC analysis and metastasis tracking
in animal models of cancer including flow cytometry, CellSearch®, and Parsortix™ (see Figure 3) and
this section will focus on these technologies. Each approach is described below and the advantages
and disadvantages are discussed and summarized in Table 2.
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Human breast cancer cell lines of differing metastatic abilities were injected into female nude (nu/nu) Figure 3. Technologies for CTC analysis and metastasis tracking in animal models of cancer. (a) Human
breast cancer cell lines of differing metastatic abilities were injected into female nude (nu/nu) mice or
NOD/SCID mice via the mammary fat pad (MFP). At several time points post-injection, mice were
sacrificed and blood (1 mL) and tissues were collected and analyzed. CTC kinetics in blood was measured
by flow cytometry (left panel; mean± SEM, n = 5 mice/group) and the incidence of lung metastasis (% of
mice in the group) was measured as assessed histopathology (right panel). Adapted from Reference [72].
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(b) Human prostate cancer cells of differing metastatic ability were injected into male nude mice
via the right dorsolateral lobe of the prostate gland. At several timepoints post injection, mice were
sacrificed and blood (100 µL) was collected and split into two 50 µL aliquots before analysis using
an adapted CellSearch® CTC assay to assess CTC kinetics between epithelial (LNCaP, C4-2B) versus
mesenchymal (PC-3M, PC-3) cell lines (left panel, mean± SEM, n = 5–12 mice/group). To compare the
difference in CTC number detected using EMT-dependent (EpCAM+) versus EMT semi-independent
(EpCAM+/HLA+) adapted CellSearch® assays in matched samples (right panel; mean ± SEM);
positive values = more CTCs detected with EMT semi-independent assay, negative values = more
CTCs detected with EMT-dependent assay. * = significant difference relative to PC-3; α = significant
difference relative to LNCaP C4-2B; δ = significant difference relative to LNCaP (p ≤ 0.05). Adapted
from Reference [45]. (c) Human PC-3 prostate cancer cells (mesenchymal phenotype) were injected into
male nude mice via the right dorsolateral lobe of the prostate gland. At several timepoints, post injection
blood (100 µL) was serially collected and analyzed using the Parsortix™ CTC analysis platform.
Table 2. Comparison of preclinical CTC analysis approaches.
Feature Flow Cytometry CellSearch® Parsortix™
Sensitivity
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6.1.1. Flow Cytometry 
Flow cytometry can be used for characterizing tumor cell dissemination patterns and kinetics in 
preclinical models of cancer metastasis [64]. Using flow cytometry in a preclinical setting, human 
cancer cells can be effectively identified among mouse leukocytes. This process has been described 
previously by Allan et al. (2005) [73]. Briefly, flow cytometry can be used to identify CTCs based on 
their size, positive staining with a FITC-conjugated anti-human leukocyte antigen (HLA) antibody, 
negative staining with a phycoerythrin (PE)-conjugated anti-mouse pan-leukocyte CD45 antibody, 
and aneuploidy DNA content based propidium iodide (PI) staining [64,73]. 
This CTC analysis approach was one of the first to allow for early detection and quantification 
of rare metastatic tumor cells in the blood of mice and this led to evidence of CTC contribution to the 
development of metastatic disease [64]. Utilizing the preclinical potential of flow cytometry analysis 
of CTCs, studies have assessed tumor cell dissemination patterns using spontaneous and 
experimental CTC/metastasis models [64] and tracked the kinetics of CTC generation in vivo by 
analyzing multiple breast cancer cell lines and their relationship between CTCs and metastasis (see 
Figure 3a) [72]. 
Flow cytometry is one of the most cost-effective CTC enumeration technologies available for 
preclinical CTC analysis, which allows for harvesting of viable cells for downstream analysis if a 
fluorescence activated cell sorting (FACS) instrument is used. However, this particular method of 
CTC enumeration relies heavily on expression of HLA on the human tumor cells [73]. As such, the 
use of cell lines with lower or absent levels of HLA expression may present difficulties with this 
technique. This is particularly relevant when considering future application of this assay to 
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This CTC analysis approach was one of the first to allow f r early detection and quantification 
of rare metastatic tumor cells in the blood of mice an  this led to evidence of CTC contribution to the 
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of CTCs, studies have assessed tu or cell dissemination patterns using spontaneous and 
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negative stai ing with a phycoerythrin (PE)-conjugated anti-mouse pan-leukocyte CD45 antibody, 
and aneuploidy DNA content based propidium io ide (PI) stai ing [64,73]. 
This CTC analy is a proach was one of the first to allow for early d ection and quantification 
of are metas atic tum r cells n the blood of mice and this led to evidence of CTC contribution to the 
d velopment of metas atic d sease [64]. Util zing the preclinical po ential of flow cytometry analy is 
of CTCs, studies have as essed tumor cell disseminat on patterns using spontaneous and 
experimental CTC/metasta is models [64] and racked the kinetics f CTC generation in ivo by 
analyzing multiple breast cancer cell lines and th i  r lationship betw en CTCs and metasta is (see 
Figure 3a) [72]. 
Flow cytometry is one o  the most cost-effective CTC e umeration techn l gies available for 
preclinical CTC analy is, which allows for harvesting of viable cells for downstream analy is if a 
fluorescence activated cell sorting (FACS) instrument is used. However, this particular method of 
CTC numeration relies heavily on expression of HLA on the human tumor cells [73]. A  such, the 
use of cell lines with ower r absent lev l  f HLA expr ssion may pr sent difficulties with this 
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6 1. Flow Cytometry 
Flow cytometry c n be used for ch racter zing tumor cell dis emination patterns and kinetics in 
pre li ical odels of ancer metasta is [64]. Using flow cytometry in a preclinical setting, human 
an r c ls can b  ffectively identifi d among mouse leukocytes. This process has been described 
pr viousl  by Allan et al. (2005) [73]. Briefly, flow cytometry can be used to i entify TCs based on 
the r size, positive stai i g with a FITC-conjugated anti-huma leukocyte antigen (HLA) antibody, 
negative stai ing with a phycoery hrin (PE)-conjug ted anti-mouse pan-leukocyte CD45 antibody, 
and aneuploidy DNA co tent based ropid um o ide (PI) stai ing [64,73]. 
This TC an ly is a proach was one o  th  first to allow fo  early d tectio  and quantif cation 
of a  metas atic tumor cells in the blo d of mice and this led to evid nce of TC contributi n to the 
development of metas atic dis ase [64]. Util zing the preclinical p ten ial of f ow cytometry analy is 
of TCs, studies have as essed tumor cell dissemination pat erns using spo taneous and 
xperimental TC/metasta is models [64] and tracked the kinetics of TC generation in ivo by 
analyzing mu tiple br ast an r cel  lines and thei  relation hip b tween TCs and metasta is (see 
Figure 3a) [72]. 
Flow cy ometry is one of the most cost-effec ve TC enum ration techn logies available for 
preclinical TC analy is, which allows for harve ting of viable cells for downstream analy is if a 
fluores nce activated cell sorting (FACS) instrument is used. However, this particular meth d of 
TC enumeration reli  heavily on expressi n of HLA n t e human tumor cells [73]. A  suc , the 
use f cell lines with lower or absent levels of HLA expression may pr sen  difficulties with this 
techniq e. This is particularly r levant when considering f ture a pl cati n of thi  assay to 
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6.1.1. Flow Cytometry 
Flow cy om try can be us  for char ct izing tu or cell disseminatio  patterns a d kinetics in 
pr clinical mod ls of cancer metastasis [64]. Usi g flow cytom try n a preclinic l setting, human 
ca c r c lls can b  ef ectively ide tified among mou e leukocyte . T is proces  has en described 
previous y b Allan et al (2005) [73]. Bri fly, flow cytometry can b  used to identify CTCs based on 
ir ize, positive staining with a FITC-conj gated anti-hum  leukocyte gen (HLA) antibody, 
n ative staining with a phycoerythrin (PE)-conj gat d ti mous  pan-leukocyte CD45 antibody, 
and aneupl idy DNA c ntent base  propidium iodide (PI) staining [64,73]. 
This CTC analysis ppr ach was one f the irst to a low f r early detection nd quantification 
of rare metastatic tumor cells in th  bloo  of mice an  th s l d to evid ce of CTC con ribution to the 
developmen of m tastatic d se se [64]. Utilizing the pr clinic l p ten ial of flow cytometry analysis 
of CTCs, studies have assessed tu or cell di semi ati n patterns using po taneous and 
experi en l CTC/ etastasis mo el [64] and tra ked the kin tics of CTC generation in vivo by 
analyzing multiple b east c cer c ll lin s a d t eir relatio ship between CTC  and m tastasis (see 
Figure 3a) [72]. 
Fl w yt me ry is ne f th  most cost-eff ctive CTC enumeration technologies available for 
precli ical CTC analysi , wh c  allow  f r h rve ing o  viable cells for downstre m analysis if a 
fluor sc nce ac vated cell sorti g (FACS) n trument is used. However, this particular method of 
CTC enum ration relies heavily o  expressi of HLA o he human tumor cells [73]. As such, the 
u  of cell lines with low r or absent level  of HLA expres ion may present difficulties with this 
techn que. This is particularly r levant whe  consid ring future appl cation of his assay to 
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m l  nude mice via the ight d rsola al lobe of the pros ate gland. A  several imepoints post 
inj ction, mi  w re sacrificed and blo d (100 µL) was collected and split int  two 50 µL aliquots 
before lysis using an dapted CellSearch® CTC assay o as s CTC k net cs between epithelial 
(LNCaP, C4-2B) versus m senchymal (PC-3M, PC-3) cell lines (left pa el, mean ± SEM, n = 5–12 
ic /g oup). To compar  the diff r nce in CTC number d tect d using EMT-dependent (EpCAM+) 
versus EMT semi-independent (EpCAM+/HLA+) d pted CellSearch® a says in matched samples 
(right panel; m an ± SEM); positive valu s = more CTCs d tected with EMT semi-independent assay, 
negat v  values = mor  CTCs d tecte  w th EMT-depe de t ssay. * = sig ific nt diff rence relative 
to PC-3; α = sig ificant diff rence relative to LNCaP C4-2B; δ = sig ificant diff rence relative to 
LNCaP (p ≤ .05). Ad pt d from R f re ce [45]. (c) Human PC-3 pros at  cancer ce ls (m senchymal 
phenotype) w re injec  into male nude mic  vi  th  ri ht dorsolateral lob of the pros ate gland. At 
several t m poi ts, p st injection blood (100 µL) wa  seri lly collect a d analyzed using the 
Par ortix™ CTC analy is platform. 
Table 2. Comparison of precl nical CTC naly is approaches. 
Feature Flow Cytometry CellSearch® Parsortix™ 
Sensit vity   ☑ 
Ca tur s cells i d pendent of phenotype  ☒ ☑ 
Ability for downstream analy is ☑ ☒ ☑ 
Accurat low b ood volume analysis ☒  ☑ 
Ease of process  ☒ ☑ 
Low cost ☑ ☒ ☑ 
Support for r search/flex bility ☑ ☒ ☑ 
Cl nical r levance 
 
☒ 
 
☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = dis ; ☑ = advantages. 
6 1. Flow Cytometry 
Flow cytom t y c n be us d for ch ract r zing tu or cell di semi atio  patterns and kinetics in 
pr clinical mod l  o  can er etasta is [64]. Us ng flow cytometry in a preclinic l setting, human 
canc r c lls can b  ef ctively id ntified among mous leuko yte . This proces  has been described 
previous y by Allan et al. (2005) [73]. Briefly, flow cytometry can be used to identify CTCs based on 
th ir ize, positiv  stai ing with a FITC-conj gated anti-hum  leukocyte gen (HLA) antibody, 
ne at ve stai ing with a phycoerythrin (PE)-c nj gat d ti-m us  pan-leukocyte CD45 antibody, 
an  aneuploidy DNA c ntent base  propidium io ide (PI) stai ing [64,73]. 
This CTC analy is a proach was on of the irst to llow f r early d ection nd quantification 
of are metas a ic tum r cells n the blood mice an  this l d t evide ce of CTC contribution to the 
d velopment of m tas atic d sease [64]. Util zing the pr clinical po en ial of flow cytometry analy is 
of CTCs, tudies have s essed tu or cell dissemi at on patterns using spontaneous and 
experi ent l CTC/m tasta is models [64] and tra ked the ki tics of CTC generation in ivo by 
ana yzing multiple br t c cer c ll in s a d t i  r latio ship b tw en CTC  and metasta is (see 
Figure 3a) [72]. 
Fl w cyt me ry is ne  th  most cost-effective CTC e ume ation techn logies available for 
preclinical CTC analysi , whic allows for h rvesting o  viable cells for downstre m analy is if a 
fluor scence ac vated cell sorting (FACS) in trument is used. H wever, this particular method of 
CTC num rati  relies heavily on expression of HLA on the human tumor cells [73]. A  such, the 
u e of cell ines with ow r r absent lev l  f HLA expres ion may pr sent difficulties with this 
technique. This is p r icularly r l v nt when c nsidering f ture a pl cation of this assay to 
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ice or NOD/SCID mice vi the a mary f t p d (MFP). At several time po nt  post-injection, mice 
w re a rificed and bloo (1 mL) and tissues w re coll cted a d analyzed. CTC k netics in blood was 
measured by low cyto try (left pa el; mea ± SEM, n = 5 mi e/group) and the incidence of lung 
etasta is (% of mice in th  g oup) wa m asured a  a essed isto th logy (right panel). Adapted 
from R f re ce [72]. (b) Hu an pros ate ca r c lls of differ ng metas tic abil ty w r  injected into 
male nud mice via the right d rsol t al lobe of the pros ate gland. A  several timepoints post 
inj ction, mic w re sa rificed and blo d (100 µL) was c llected and split int  two 50 µL aliquots 
b fo e n lysis using an adapted C llSe rch®  assay to ss CTC k netics b tween epithelial 
(LN aP, C4-2B  v rsus m s nchymal (PC-3M, PC-3) cell li es (left pa el, mean ± SEM, n = 5–12 
ic /g oup). To compar the diff nce in CTC umb r tect d using EMT-dep dent (EpCAM+) 
v rsus EMT semi-indepe dent (EpCAM+/HLA+) a pted C llSearch® says in matched samples 
(right anel; m n ± SEM); positive valu s = more CTC  d tected with EMT emi-indep dent assay, 
n gative valu s = more CTCs d t cte  with EMT-dep de ssay. * = signif c nt diff rence relative 
to PC-3; α = significant diff rence rela ive to LNCaP C4-2B; δ = significant diff rence relative to 
LNCaP (p ≤ .05). Adapt d from R f re ce [45]. c) Human PC-3 pro at  can r ce ls (m senchymal 
phenotype) w r  inject d into male nu e mice vi  th  righ  dors l teral be of he pros ate gland. At 
several t m poi t , p st injection blood (100 µL) wa  serially collected a d analyzed using the 
Par ortix™ CTC analy is platform. 
Table 2. Com arison of precl nical CTC analy is approaches. 
Fea ure F ow Cytometry C llSearch® Parsortix™ 
Sensit vity  ☑ ☑ 
Captur s cells i dep dent of phenotype  ☒ ☑ 
Ability f r downstre m analy is ☑ ☒ ☑ 
Accurat low b ood volume analysis ☒  ☑ 
Ease of process  ☒ ☑ 
Low cost ☑ ☒ ☑ 
Supp t for r search/flex bility ☑ ☒ ☑ 
Cl nical r levance 
 
☒ 
 
☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = is ; ☑ = dvantages. 
6 1. Flow Cytometry 
Flow cytome y c n be used for ch ract r zing tumor c ll dis emi atio  patterns and kinetics in 
pre li ical od l  of ancer metasta is [64]. Using flow cyto etry in a preclinic l setting, human 
an er c ls can b  ef ectivel  identifi d among mouse leukocytes. This process has been described 
pr vious  by Allan et al. (2005) [73]. Briefly, flow cytometry can be used to i e tify TCs based on 
th r size, posi ive sta i g with a FITC-conjugated anti-huma leukocyte gen (HLA) antibody, 
negative stai ing with phyc ery hrin (PE)- nj g ted anti-mous  pan-leukocyte CD45 antibody, 
and a euploidy DNA c tent base  ropid um o ide (PI) stai ing [64,73]. 
This TC analy is a proach was on  o  th first to allow f  early d ecti  and quantif cation 
of a  metasta ic tum r cells n the blo d of mice a  this led to evid nce of TC contributi n to the 
d velopment of m tas at c d s as  [64]. Uti zing the preclinical p en ial of f ow cytometry analy is 
of TCs, stu ie  have as essed tu or cell disseminat on pat erns using spo taneous and 
xperimental TC/metasta s models [64] and tra ked the ki tics of TC generation in ivo by 
ana yzing mu tip e br a t r c ll i es a d th i  r l tion hip b tw en TC  and metasta is (see 
Figure 3a) [72]. 
Fl w cyt metry is on  o  th  most cost-effec ve TC e um ration techn logies available for 
preclinical TC analysi , which a lows for h rv ting of viable cells for downstre m analy is if a 
fluor s nce ac vated cell sorting (FACS) instrument is used. However, this particular meth d of 
TC num rati  reli  heavily on expressi n of HL  n t e human tumor cells [73]. A  suc , the 
use f c ll lines with ower r absent l vel f HLA xpress on may pr sen difficulties with this 
t chniq e. This is p r cularly levant when considering f ture a pl cati n of thi  assay to 
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mice or NOD/SCID mice via the mammary fat pad (MFP). At several time points post-injection, mice 
ere sacrificed and blood (1 mL) and tissues were collected and analyzed. CTC kinetics in blood was 
easured by flo  cyto etry (left anel; ean ± SEM, n = 5 mice/group  and the incidence of lung 
me astasis (% of mice in the group) was measured as assessed histopathology (right pa el). Adapted 
from Reference [72]. (b) Human prostate cancer ce ls of differing metastatic ability were injected into 
male nude ice via the right orsola era  lobe of the prosta e gland. At several timepoints post 
injection, mice were sacrificed an  blood (100 µL) was collected and split into two 50 µL aliquots 
before analysis using an adapted ellSearch® CT  assay to assess CTC kinetics between epithelial 
(LNCaP, C4-2B) versus mesenchy al (P -3M, PC-3) cell lines (left panel, mean ± SEM, n = 5–12 
ce/group). To compare the difference in TC number detected using EMT-dependent (EpCAM+) 
versus E T se i-independent (Ep AM+/HLA+) adapted CellSearch® assays in matched samples 
(right panel; mean ± SEM); positive values = more CTCs etecte with EMT semi-independent assay, 
negative values = more CTCs detected wi h EMT-dependent assay. * = significant difference relative 
to PC-3; α = signi icant difference relative to LNCaP C4-2B; δ = significant difference relative to 
LNCaP (p ≤ 0.05). A apte  fro  Reference [45]. (c) Human PC-3 prostate cancer cells (mesenchymal 
phenotype) were injected into male nude m ce via the right orsolateral lobe of the prostate gland. At 
several timepoints, post injection blood (100 µL) was serially collected and analyzed using the 
Parsortix™ CTC analysis platform. 
Table 2. Comparison of preclinical CTC analysis approaches. 
Feature Flow Cytometry CellSearch® Parsortix™ 
S sitivity ☑ ☑  
Captu s cells indepe dent of phenotype    
bi ity f r down tream l i   ☒  
Ac urat low bl od volume analysis    
Ease of process   ☑ 
Low ost ☑☑  ☑☑ 
Support for research/flexibility  ☒  
Clinical relevance 
 
☒ 
 
☑☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = disadvantages; ☑ = advantages. 
6.1.1. Flow Cytometry 
Flow cyto etry can be used for characterizing tumor cell dissemination patterns and kinetics in 
preclinical models of cancer metastasis [64]. Using flow cytometry in a preclinical setting, human 
cancer cells can be effectively identified a ong mouse leukocytes. This process has been described 
previously by Allan et al. (2005) [73]. Briefly, flow cytometry can be used to identify CTCs based on 
their size, positive staining with a FITC-conjugated anti-hu an leukocyte antigen (HLA) antibody, 
negative staining with a phycoerythrin (PE)-conjugated anti-mouse pan-leukocyte CD45 antibody, 
and aneuploidy DNA content based propidium iodide (PI) staining [64,73]. 
This CTC analysis approach was one of the first to allow for early detection and quantification 
of rare metastatic tumor cells in the blood of mice and this led to evidence of CTC contribution to the 
development of metastatic disease [64]. Utilizing the preclinical potential of flow cytometry analysis 
of CTCs, studies have assessed tumor cell dissemination patterns using spontaneous and 
experimental CTC/metastasis models [64] and tracked the kinetics of CTC generation in vivo by 
analyzing multiple breast cancer cell lines and their relationship between CTCs and metastasis (see 
Figure 3a) [72]. 
Flow cytometry is one of the most cost-effective CTC enumeration technologies available for 
preclinical CTC analysis, which allows for harvesting of viable cells for downstream analysis if a 
fluorescence activated cell sorting (FACS) instrument is used. However, this particular method of 
CTC enumeration relies heavily on expression of L  on the hu an tumor cells [73]. As such, the 
use of cell lines with lower or absent levels of HLA expression may present difficulties with this 
technique. This is particularly relevant when considering future application of this assay to 
Abil ty for downstream analysi
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mice or NOD/SCID mice via the mammary fat pa  (MFP). At several time points post-injection, mice 
were sacrificed and blood (1 mL) and tissues were collected and analyzed. CTC kinetics in blood was 
measured by flow cytometry (left panel; mean ± SEM, n = 5 mice/group) and the incidence of lung 
metastasis (% of mice in the group) was measured as assessed histopathology (right panel). Adapted 
from Reference [72]. (b) Human prostate cancer cells of differing metastatic ability were injected into 
male nude mice via the right dorsolateral lobe of the prostate gland. At several timepoints post 
injection, mice were sacrificed and blood (100 µL) was collected and split into two 50 µL aliquots 
before analysis using an adapted CellSearch® CTC assay to assess CTC kinetics between epithelial 
(LNCaP, C4-2B) versus mesenchymal (PC-3M, PC-3) cell lines (left pa el, mean ± SEM, n = 5–12 
mice/group). To compare the difference in CTC number detected using EMT-dependent (EpCAM+) 
versus EMT semi-independent (EpCAM+/HLA+) adapted CellSearch® assays in matched samples 
(right panel; mean ± SEM); positive values = more CTCs detected with EMT semi-independent assay, 
negative values = more CTCs detected with EMT-dependent assay. * = significant difference relative 
to PC-3; α = significant difference relative to LNCaP C4-2B; δ = significant difference relative to 
LNCaP (p ≤ 0.05). Adapted from Reference [45]. (c) Human PC-3 prostate cancer cells (mesenchymal 
phenotype) were injected into male nude mice via the right dorsolateral lobe of the prostate gland. At 
several timepoints, post injection blood (100 µL) was serially collected and analyzed using the 
Parsortix™ CTC analysis platform. 
Table 2. Comparison of preclinical CTC analysis approaches. 
Feature Flow Cytometry CellSearch® Parsortix™ 
Sensi ivity  ☑   
Captures cells independent of phenotype    
Ability for downstream analysis ☑  ☑ ☑ 
Accurate low blood volume analysis ☒  ☑  
Ease of process ☒   
Low cost ☑☑☑  ☑  
Support for research/flexibility ☑☑ ☒ ☑☑☑ 
Clinical relevance 
 
☒ 
 
☑☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = disadvantages; ☑ = advantages. 
6.1.1. Flow Cytometry 
Flow cytometry can be used for characterizing tumor cell dissemination patterns and kinetics in 
preclinical models of cancer metastasis [64]. Using flow cytometry in a preclinical setting, human 
cancer cells can be effectively identified among mouse leukocytes. This process has been described 
previously by Allan et al. (2005) [73]. Briefly, flow cytometry can be used to identify CTCs based on 
their size, positive staining with a FITC-conjugated anti-human leukocyte antigen (HLA) antibody, 
negative staining with a phycoerythrin (PE)-conjugated anti-mouse pan-leukocyte CD45 antibody, 
and aneuploidy DNA content based propidium iodide (PI) staining [64,73]. 
This CTC analysis approach was one of the first to allow for early detection and quantification 
of rare metastatic tumor cells in the blood of mice and this led to evidence of CTC contribution to the 
development of metastatic disease [64]. Utilizing the preclinical potential of flow cytometry analysis 
of CTCs, studies have assessed tu or cell dissemination patterns using spontaneous and 
experimental CTC/metastasis models [64] and tracked the kinetics of CTC generation in vivo by 
analyzing multiple breast cancer cell lines and their relationship between CTCs and metastasis (see 
Figure 3a) [72]. 
Flow cytometry is one of the most cost-effective CTC enumeration technologies available for 
preclinical CTC analysis, which allows for harvesting of viable cells for downstream analysis if a 
fluorescence activated cell sorting (FACS) instrument is used. However, this particular method of 
CTC enumeration relies heavily on expression of HLA on the human tumor cells [73]. As such, the 
use of cell lines with lower or absent levels of HLA expression may present difficulties with this 
technique. This is particularly relevant when considering future application of this assay to 
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mice or NOD/SCID mice via the mammary f t pad (MFP). At several time points post-injection, mice 
were sacrificed nd blood (1 mL) and tissues were coll cted and analyz d. CTC kinetics in blood was 
measured by flow cytometry (left panel; me  ± SEM, n = 5 mice/group) and the incidence of lung 
metastasis % of ic  in the group) was measured as as ess d histopathology (ri ht nel). Adapted 
from Reference [72]. (b) H man prostate cancer cells f differing metastatic bility were injected into 
male n de mice via the right dorsolateral lobe f the p os ate gland. At several timepoints post 
njection, mice wer  sacrificed and blood (100 µL) was collected and spli  int  wo 50 µL aliquots 
before analysis using an adapted CellSear h® CTC assay to assess CTC kinetic  between epithelial 
(LNCaP, C4-2B) versus mesenchym l (PC-3M, PC-3) cell l nes (left panel, mean ± SEM, n = 5–12 
mice/group). To compa e the difference in CTC number det cted using EMT-dependent (EpCAM+) 
versus EMT semi-independent (EpCAM+/HLA+) adapted CellSearch® assays in matched samples 
(right panel; mean ± SEM); positive values = more CTC  detected wit  EMT semi-independent assay, 
negative values = more CTCs detecte  with EMT-dependent assay. * = signific nt difference rel tive 
to PC-3; α = significant difference relative to LNCaP C4-2B; δ = sig ificant difference relative to 
LNCaP (p ≤ 0.05). Adapted from Reference [45]. (c) Human PC-3 prostat  cancer cells (mesenchymal 
phenotype) wer  inject d into male nud  mice via the right dorso teral lobe of the prostate gland. At 
s veral timepoints, post inj ctio blo  (100 µL) was serially collected and analyzed usi g the 
Parsort x™ CTC analysis platform. 
Table 2. Comparison of preclinical CTC analysis approaches. 
Feature Flow Cytometry CellSearch® Parsortix™ 
Sensitivity ☑ ☑ ☑  
Captures cells independent of phenotype ☒   
bility for d wnstream analysis ☑   
Accurate low blood volume analysis  ☑  
E se of process ☒  ☑ 
Low cost ☑☑☑  ☑☑ 
Support for research/flexibility ☑   
Clinical relevance 
 
☒ 
 
☑☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = disadvantages; ☑ = t . 
6.1.1. Flow Cytometry 
Flow cytometry can be used for characterizing tumor c ll dissemination patterns and kinetics in 
p eclinical mo els of cancer m tastasis [64]. U ing flow cytom try i  a preclinical setting, hum n 
cancer cells can be ffectively id ntified am ng mouse leukocytes. This pr cess has been described 
pr viously by Allan t al. (2005) [73]. Briefly, flow cytometry can be used to identify CTCs based on 
their size, positiv  staining with a FITC-conjugated anti-huma  leukocyte ntigen (HLA) tibody, 
neg tive staini g with a phycoerythrin (PE)-conj gated anti-mo se pan-leukocyt  CD45 antibody, 
and aneuploidy DNA content based pr pidium io ide (PI) staining [64,73]. 
This CTC nalysis approach was one of the first to allow for early detecti n and quantification 
of rare metastatic tum r cells in the bl od f mice and this led to evi ence of CTC contribution to the 
development of metastatic diseas  [64]. Utilizing the pr clinical p tential of flow cytometry analysis 
of CTCs, studi s have assessed tumor cell disse inati n patterns using pontaneous and 
experimental CTC/metastasis models [64] and tracked the kineti s of CTC g eration in vivo by 
analyzing multiple breast cance  cell lines d th ir relatio ship between CTCs and metastasi  (see 
Figure 3a) [72]. 
Flow cytometry is one f the most cost-eff ctive CTC enumeration technologies available for 
preclinical CTC analysis, which allow  for harvesting of vi ble cell  for downstream analysis if  
fluorescence activat d cell so ting (FACS) instrument is used. However, this particular method of 
CTC enumeration relies h avily on expression of HLA on the human tu or cells [73]. As such, the 
use of cell lines with lower or absent levels of HLA expression may present difficulties with this 
tec nique. This is particularly relevant whe  consid ring future application of this assay to 
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mice or NOD/SCID mice via th  mammary fat pad (MFP). At several time points post-injection, mice 
were acrificed and bloo (1 mL) and tissues wer  collected  analyze . CTC kinetics in blood was 
measured by fl w cytometry (l ft anel; ean ± SEM, n = 5 mice/group) and the incidence of lung 
met tasis (% of mice in the group) was measured as as essed his opathology (right panel). Adapted 
from Ref rence [72]. (b) Human pro t t  c ncer cells of iffering metastatic ability were injected into 
male nude ice via the right orsolateral lobe of the prostate gland. At several timepoints post 
injection, mice were a rificed an  blood (100 µL) was col ected and split into two 50 µL aliquots 
before naly is using an adapted ellSearch® CTC assay to ass ss CTC kinetics between epithelial 
(LNCa , C4-2B) v sus mesenchymal (PC-3M, PC-3) cell lines (left panel, mean ± SEM, n = 5–12 
ice/group). To compare the difference in CTC number detected using EMT-dependent (EpCAM+) 
versus T se -independ nt (EpCAM+/HLA+) dapted C llSearch® assays in matched samples 
(right panel; m an ± SEM); positive values = ore CTCs detected with EMT semi-ind pendent assay, 
negative valu s = mo  CTCs detected with EMT-dep d nt assay. * = significant difference relative 
to PC-3; α = significant difference relative to LNCaP C4-2B; δ = significant difference relative to 
LNCaP (p ≤ 0 05 . Adapte  from Refer nce [45]. (c) Huma  PC-3 prostate cancer cells (mesenchymal 
phenotype) were injected into male nude mice via the right dorsol teral lobe of the prostate gland. At 
several timepoints, post injection bloo  (100 µL) was serially collected and analyzed using the 
Parsortix™ CTC analysis platform. 
Table 2. Comparison of preclinical CTC analysis approaches. 
Feature Flow Cytometry CellSearch® Parsortix™ 
Se itivity   
Captures cells indepe dent of phenotype  ☒  
bility for down tream analysis  ☑  
Accura  low blood volume analysis  ☑☑  
Ease of process    
Low cost ☑☑ ☒ ☑☑ 
Support for research/flexibility ☑  ☒ ☑☑  
Clinical relevance 
 
☒ 
 
☑☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = disadvantages; ☑ = advantages. 
6.1.1. Flow Cyto etry 
Flow cy ometry can be use  for char cterizing tumor cell dissemination patterns and kinetics in 
preclinical models of cancer metastasis [64]. Usi g flow cytom try in a preclinical setting, human 
cancer cells can be effectively identified a ong mou e leukocytes. This process has been described 
previously b  Allan et al. (2005) [73]. Bri fly, flow cytometry can b  used to identify CTCs based on 
eir size, positive staini g with a FITC-conjugated anti-human leukocyte antigen (HLA) antibody, 
n gative staining with a phycoerythrin (PE)-conjugated anti-mouse pan-leukocyte CD45 antibody, 
and aneuploidy DNA content bas d propidium iodide (PI) staining [64,73]. 
This CTC analysis appr ach was one of the first to allow for early detection and quantification 
f rare metastatic tumor cells in th  blood of mi e and th s led to evid nce of CTC contribution to the 
developm nt of metastatic dise se [64]. Utilizing the pr clinic l potential of fl w cytometry analysis 
of TCs, studies have assessed tumor c ll di seminati n patterns using spontaneous and 
ex erim ntal CTC/metastasis model [64] and track d the kinetics of CTC generation in vivo by 
analyzing multiple b east ca cer cell lin s and their relationship between CTCs and metastasis (see 
Figure 3a) [72]. 
Fl w ytometry is one of the most c st-effectiv  CTC enumeration technologies available for 
preclinical CTC analysis, wh ch allow  f r harve ing of viable cells for downstream analysis if a 
fluorescence activated cell sorti g (FACS) i strument is sed. However, this particular method of 
CTC enumerati n relies h avily on expressi n of L  on the human t mor cells [73]. As such, the 
u e of cell lines with lower or absent level  of HLA xpression may present difficulties with this 
technique. This is particularly relevant when considering future application of this assay to 
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ice r NOD/SCID mice via the ma mary fat pad (MFP). At several time p ints post-injection, mice 
re sacrificed and blood (1 mL) an  tissues w re collected and analyz d. CTC ki etics in blood was 
easured by flow cyto try (left p n l; mean ± SEM, n = 5 mice/group  and th  incidence of lung 
metasta is (% of mic  in the gr up) was m asured as as essed histopath logy (right panel). Adapted 
from R f rence [72]. (b) Human pros ate cancer c ls of differi g metas atic ability w re injected into 
m l  nude mice via the right dorsola era  lobe of the pros ate gland. At several timepoints post 
injection, mice w r sacrificed and blood (100 µL) was collected and split into two 50 µL aliquots 
b fore analysis using an dapted CellSearch® CT  assay o as ess CTC kinetics between epithelial 
(LNC P, C4-2B) v rsus m senchy al (PC-3M, PC-3) cell lines (left panel, mean ± SEM, n = 5–12 
m c /group). To compar  the diff rence in TC number d tected using EMT-dependent (EpCAM+) 
versus EMT emi-independent (Ep AM+/HLA+) adapted CellSearch® assays in matched samples 
(right panel; mean ± SEM); positiv  values = more CTCs te ted with EMT s mi-independent assay, 
egat ve valu s = mor  CTCs d tected w th EMT-dependent assay. * = significant diff rence relative 
to PC-3; α = signi ica t diff rence relative to LNCaP C4-2B; δ = ignificant diff rence relative to 
LNCaP (p ≤ .05). Ad pted fro  R f rence [45]. (c) Human PC-3 r s ate cancer cells (m senchymal 
phen type) w re injec e  into male nude m c  via th  ri ht dorsolateral lobe of the pros ate gland. At 
several timepoints, post injection blood (100 µL) wa  serially collected and analyzed using the 
Parsortix™ CTC analy is platform. 
Table 2. Comparison of precl nical CTC analy is approaches. 
Feature Flow Cytometry CellSearch® Parsortix™ 
S sit vity    
Ca tu s cells independent of phenotype    
Abi ity f r down tream an ly is    
Accurate low bl od volume analysis   ☑ 
Ease of process    
Low cost ☑  ☑ 
Support for r search/flex bility  ☒ ☑ 
Cl nical r levance 
 
☒ 
 
☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = disadvantages; ☑ = advantages. 
6 1. Flow Cyto etry 
Flow yto etry can be used for ch racter zing tumor cell di semination patterns and kinetics in 
pr clini al models o  can er etasta is [64]. Us ng flow cytometry in a preclinical setting, human 
cancer cells can b  eff ctively id ntified among mous  leuko ytes. This proce s has been described 
previously by All n et al. (2005) [73]. Briefly, flow cyt metry can be used to identif  CTCs based on 
their size, ositiv  staining with a FITC-co jugated anti-human leukocyte tigen (HLA) antibody, 
negat ve stai ing with a hycoerythrin ( E)-co ju ated anti-m use pan-leukocyte CD45 antibody, 
a  aneu loidy DNA c tent based pr pidium io ide (PI) stai i g [64,73]. 
This CTC analy is a proach was on  of the first to ll w for early d tection and quantification 
of are metas atic tumor cells in the blood mice and this led t  evidenc  of CTC contribution to the 
d velopment of metas atic dis ase [64]. Util zing the pr clinical potential of flow cytometry analy is 
of CTCs, studies have s essed tumor cell dis emination patterns using spontaneous and 
experiment l CTC/m tasta is models [64] and tracked the kinetics of CTC generation in ivo by 
ana yzing multiple br st cancer c ll lines and thei  relationship b tween CTCs and metasta is (see 
Figure 3a) [72]. 
Flow cytometry is one of th  most cost-eff ctive CTC enume ation techn logies available for 
preclini al CTC analy is, which allows for harvesting of viable cells fo  downstream analy is if a 
fluorescence activated cell orting (FACS) in trument is used. H wever, this particular method of 
CTC enum ati n r lies heavily on expression f HLA on the hu an tumor cells [73]. A  such, the 
use of cell ines with lower or absent levels of HLA ex ression may pr sent difficulties with this 
technique. This is particularly r l v nt when c nsidering f ture a plication of this assay to 
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ice or NOD/SCID mic  via the a mary f t p d (MFP). At several time point  post-injection, mice 
w re a rific d and b oo  (1 mL) and tissues w re collecte  and analyzed. CTC k netics in blood was 
measur d by flo  cytometry (left panel; mea ± SEM, n = 5 mice/group) and the incidence of lung 
metasta is (% of mic  in th  group) was measured as essed histopath logy (right pa el). Adapted 
from R f rence [72]. (b) Hu an pros ate can r c lls of differing metas tic ability w r  injected into 
male nud mice via the right dorsol t ral lobe of the pros ate gland. At several timepoints post 
injection, mic  w re s rificed and blood (100 µL) was collected and split into two 50 µL aliquots 
b fo e analysis using an adapted C llSearch® CTC ssay to ess CTC k netics b tween epithelial 
(LN aP, C4-2B  v rsus m s chymal (PC-3M, PC-3) cell lines (left panel, mean ± SEM, n = 5–12 
mice/group). To compar the diff rence in CTC numb r d tected using EMT-d p dent (EpCAM+) 
versus EMT semi-indepe dent (EpCAM+/HLA+) a apted C llSearch® ass y  in matched samples 
(right panel; mean ± SEM); positive values = more CTCs d tecte  with EMT semi-indep dent assay, 
nega ive valu s = more CTCs d tected with EMT-dep dent assay. * = significant diff rence relative 
to PC-3; α = significant diff rence rela ive to LNCaP C4-2B; δ = signifi ant diff rence relative to 
LNCaP (p ≤ .05). A apted from R f rence [45]. c) Human PC-3 pros ate can r cells (m senchymal 
phenotype) w r  injected into male nu mice via th  right orsol teral l be of t  pros ate gland. At 
several timepoint , post injection blood (100 µL) wa  serially collected and analyzed using the 
Parsortix™ CTC analy is platform. 
Table 2. Com arison of precl nical CTC analy is approaches. 
Fea ure Flow Cytometry C llSearch® Parsortix™ 
Sensit vity  ☑  
Captur s cells indep dent of phenotype  ☒  
Ability f r downstre m l i  ☑  ☑ 
Ac urate low blood volume analysis  ☑ ☑ 
Ease of process    
Low ost ☑ ☒ ☑ 
Supp t for r search/flex bility ☑ ☒ ☑ 
Cl nical r levance 
 
☒ 
 
☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = is dvantages; ☑ = dvantages. 
6 1. Flow Cytometry 
Flow cytome ry can be used for ch racter zing tumor c ll dissemination patterns and kinetics in 
preclinical mo els of ancer metasta is [64]. Using flow cyto etry in a pre linical setting, human 
r cells can b  effectivel  identified among mo  leukocytes. This proc ss has been described 
previousl  by Allan et al. (2005) [73]. Briefly, flow cytometry can be used to identify TCs based on 
their size, posi ive sta ing with a FITC-conjugated anti-h an leukocyte antigen (HLA) antibody, 
negative stai ing with  phyc erythrin (PE)- o jugated anti-mouse pan-leukocyte CD45 antibody, 
and aneu l idy DNA co tent based ropidium o ide (PI) stai ing [64,73]. 
This TC analy is a proach was on  of th  first to allow f  early d tecti  and quantif cation 
of r  meta atic tumor cells in t e blo d of mice and this led to evid nce of TC contributi n to the 
development of metas at c dis as  [64]. Uti zing the preclinical pote tial of flow cytometry analy is 
of TCs, studie  have s essed tumor cell dissemination p tterns using spo taneous and 
xperimental TC/meta ta s models [64] and track d the kinetics of TC generation in ivo by 
ana yzing mu tiple breast an r cell li es and thei  r l tion hip b tween TCs and metasta is (see 
Figure 3a) [72]. 
Flow cytometry is n  of the most cost-effective TC e umeratio  techn logies available for 
preclinical TC analy is, which a low for harv sting of viable cells for downstream analy is if a 
fluor nce activated cell sorting (FACS) instrument is used. However, this particular meth d of 
TC enumeration relies heavily on expressi n of HL  on t e human tumor cells [73]. A  suc , the 
u e of c ll lines with lower r absent l vels of HLA xpressi  may pr sent difficulties with this 
t chnique. This is part cularly levant when considering f ture a pl cati n of thi  assay to 
Acc ate low blood volume analysis
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ice or NOD/SCID mice via the mammary fat pad (MFP). At several time points post-injection, mice 
were sacrificed and b ood (1 mL) and tissues were collected and analyzed. CTC kinetics in blood was 
measured by flo  cytometry (left pa el; mean ± SEM, n = 5 mice/group) an  the incidence of lung 
etastasis (% of mice in the group) was measured as assessed histopathology (right panel). Adapted 
from Reference [72]. (b) Human prostate cancer cells of differing metastatic ability were injected into 
male nude mice via the right dorsolateral lobe of the prostate gland. At several timepoints post 
injection, mice were sacrificed and blood (100 µL) was collected and split into two 50 µL aliquots 
before analysis using an adapted CellSearch® CTC assay to assess CTC kinetics between epithelial 
(LNCaP, C4-2B) versus mesenchy al (PC-3M, PC-3) cell lines (left panel, mean ± SE , n = 5–12 
mice/group). To compare the difference in CTC number detected using EMT-dependent (EpCAM+) 
versus EMT semi-independent (EpCAM+/HLA+) adapted CellSearch® assays in matched sa ples 
(right panel; mean ± SEM); positive values = more CTCs etecte  with EMT semi-independent assay, 
nega ive values = more CTCs detected with EMT-dependent assay. * = significant difference relative 
to PC-3; α = significant difference relative to LNCaP C4-2B; δ = significant difference relative to 
LNCaP (p ≤ 0.05). A apted from Reference [45]. (c) Human PC-3 prostate cancer cells (mesenchymal 
phenotype) were injected into male nude mice via the right orsolateral lobe of he prostate gland. At 
several timepoints, post injection blood (100 µL) was serially collected and analyzed using the 
Parsortix™ CTC analysis platf rm. 
Table 2. Comparison of preclinical CTC analysis approaches. 
F ature Flow Cytometry CellSearch® Parsortix™ 
Sensitivity  ☑☑☑ ☑☑☑ 
Captures cells independent  phen type ☒ ☒ ☑ 
Ability for downstre m analysis ☑ ☒ ☑ ☑ 
Ac urate low blood volume an lysis ☒  ☑☑☑ 
Ease of process ☒ ☒ ☑ 
Low cost ☑☑☑  ☑  
Support for research/flexibility ☑  ☑  
Clinical relevance 
 
☒ 
 
☑☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = disadvantages; ☑ = advantages. 
6.1.1. Flow Cyt metry 
Flow cytometry can be used for characterizing tumor cell dissemination patterns and kinetics in 
preclinical models of cancer metastasis [64]. Using flow cyto etry in a preclinical setting, human 
cancer cells can be effectively identified among mouse leukocytes. This process has been described 
previously by Allan et al. (2005) [73]. Briefly, flow cytometry can be used to identify CTCs based on 
their size, positive staining with a FITC-conjugated anti-human leukocyte antigen (HLA) antibody, 
negative staining with a phycoerythrin (PE)-conjugated anti-mouse pan-leukocyte CD45 antibody, 
and aneuploidy DNA content based propidium iodide (PI) staining [64,73]. 
This CTC analysis approach was one of the first to allow for early detection and quantification 
of rare metastatic tumor cells in the blood of mice and this led to evidence of CTC contribution to the 
development of metastatic disease [64]. Utilizing the preclinical potential of flow cytometry analysis 
of CTCs, studies have assessed tumor cell dissemination patterns using spontaneous and 
experimental CTC/metastasis models [64] and tracked the kinetics of CTC generation in vivo by 
analyzing multiple breast cancer cell lines and their relationship between CTCs and metastasis (see 
Figure 3a) [72]. 
Flow cytometry is one of the most cost-effective CTC enumeration technologies available for 
preclinical CTC analysis, which allows for harvesting of viable cells for downstream analysis if a 
fluorescence activated cell sorting (FACS) instru ent is used. However, this particular ethod of 
CTC enumeration relies heavily on expression of HLA on the human tumor cells [73]. As such, the 
use of cell lines with lower or absent levels of HLA expression may present difficulties with this 
technique. This is particularly relevant when considering future application of this assay to 
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mice or NOD/SCID mice via the ammary fa pad (MFP). At several time points post-injection, mice 
were sacrificed and blood (1 mL) and tissues were co lected and analyzed. CTC kinetics in blood was 
easured by flow cytometry (left anel; ean ± SEM, n = 5 mice/group) and the incidence of lung 
me astasis (% of mice in the group) was measured as ssessed his opathology (right panel). Adapted 
from Reference [72]. (b) Human prostate cancer cells of differing metastatic ability were injected into 
male nude ice via the ight orsolat ral lobe of the prostate gland. At several imepoints post 
inj ction, i  were sacrificed an  blood (100 µL) was collected and split into two 50 µL aliquots 
before alysis using an dapted ellSearch® CT  assay to asse s CTC kinet cs between epithelial 
(LNCaP, 4-2B) versus mesenchymal (PC-3M, P -3) cell lines (left panel, mean ± SEM, n = 5–12 
mice/group). To co pare the difference in CTC number detected using EMT-dependent (EpCAM+) 
versus EMT se i-independent (EpCAM+/HLA+) dapted CellSearch® assays in matched samples 
(right panel; mean ± SEM); positive values = more C Cs etected with EMT semi-independent assay, 
negativ  values = more CTCs detected with EMT-depende  assay. * = sig ificant difference relative 
to PC-3; α = sig ificant difference relative to LNCaP C4-2B; δ = sig ificant difference relative to 
LNCaP (p ≤ 0.05). Adapte  fro  Reference [45]. (c) Human PC-3 prostate cancer cells (mesenchymal 
phenotype) were injected into male nude mice via th  right dorsolateral lob of the prostate gland. At 
several timepoints, post injection blood (100 µL) was seri lly collect and analyzed using the 
Parsortix™ CTC analysis platform. 
Table 2. Comparison of preclinical CTC nalysis approaches. 
F ature Flow Cytometry CellSearch® Parsortix™ 
Se itivity   ☑☑☑ 
Captures cells ind pe dent of phenotype ☒ ☒ ☑ 
bility f r d nstream an lysis ☒  
Accura e low bl od volum  analysis ☒  ☑☑☑ 
Ease of proces  ☒  ☑ 
Low co t ☑  ☑☑ 
Support for rese rch/flexibility ☑☑ ☒ ☑  
Clinical relevance 
 
☒ 
 
☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = disadvantages; ☑ = advantages. 
6.1.1. Fl w Cyt ry
Flow cyto try can be us d for characterizing tu or cell dissemination patterns and kinetics in 
pr clinical odels of cancer metastasis [64]. Using flow cytometry in a preclinical setting, human 
cancer c lls can be effectively identified among mouse leukocyte . This proces  has been described 
previously by Allan et al. (2005) [73]. Briefly, flow cytometry can be used to identify CTCs based on 
their ize, positive staining with a FITC-conj gated anti-hum  leukocyte antigen (HLA) antibody, 
ne ative staining with a phycoerythrin (PE)-conjugat d ti-mouse pan-leukocyte CD45 antibody, 
and aneuploidy DNA content based propidium iodide (PI) staining [64,73]. 
This CTC analysis approach was one of the irst to allow for early detection nd quantification 
of rare metastatic tu or cells in the blood of mice and this l d to evide ce of CTC contribution to the 
develop ent of metastatic disease [64]. Utilizing the preclinical poten ial of flow cytometry analysis 
of CTCs, studies have assessed tumor cell dissemi ation patterns using spontaneous and 
experi ental CTC/metastasis models [64] and tracked the kinetics of CTC generation in vivo by 
analyzing multiple breast cancer cell lin s and t eir relatio ship between CTCs and metastasis (see 
Figure 3a) [72]. 
Flow cytome ry is ne f the most cost-effective CTC enumeration technologies available for 
preclinical CTC analysis, whic  allo s for harvesting o  viable cells for downstream analysis if a 
fluorescence activated cell sorting (FACS) in trument is used. However, this particular method of 
CTC enumeration relies heavily on expression of L  on the hu an tumor cells [73]. As such, the 
u e of cell lines with low r or absent levels of HLA expres ion may present difficulties with this 
technique. This is particularly relevant when considering future appl cation of this assay to 
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mice or NOD/SCID mice vi  the ma mary fat pad (MFP). At several time points post-injection, mice 
w re sacrificed and blood (1 mL) and tissues w re coll cted and analyzed. CTC kinetics in blood was 
easured by flow cytometry (left anel; ean ± SEM, n = 5 ice/group) and the incidence of lung 
e asta is (% of mice in the g oup) wa m asured as as essed histo th logy (right pa el). Adapted 
from R f rence [72]. (b) Human pros ate cancer cells of differ ng metas atic abil ty w re injected into 
male nude ice via the right rsola e al lobe of the pros a e gland. At several timepoints post 
inj ction, mice w re sacrificed an  blood (100 µL) was collected and split into two 50 µL aliquots 
before analysis using an adapted CellSearch® CT  assay to as ess CTC kinetics between epithelial 
(LNCaP, C4-2B) versus m senchymal (P -3M, PC-3) cell lines (left panel, ean ± SEM, n = 5–12 
mice/g oup). To compare the diff rence in CTC number d tected using EMT-dependent (EpCAM+) 
versus EMT se i-independent (EpCAM+/HLA+) adapted CellSearch® assays in matched samples 
(right panel; mean ± SEM); positive values = more CTCs tected with EMT semi-independent assay, 
negative values = more CTCs d tected wi h EMT-dependent ssay. * = signific nt diff rence relative 
to PC-3; α = significant diff rence relative to LNCaP C4-2B; δ = significant diff rence relative to 
LNCaP (p ≤ .05). Adapt  fro  R f rence [45]. (c) Human PC-3 pros ate cancer ce ls (m senchymal 
phenotype) w re inject d into male nude mice vi  the right dorsolateral lobe of the pros ate gland. At 
several t m poi ts, p st injection blood (100 µL) wa  serially collected a d analyzed using the 
Parsortix™ TC analy is platform. 
Table 2. Comparison of precl nical CTC analy is approaches. 
Featur  Flow Cytometry CellSearch® Parsortix™ 
Se it vity  ☑ ☑ 
Captur s cells i depe dent of phenotype  ☒ ☑ 
bility f r downstream l i  ☑ ☒  
A curate low b od volume analysis ☒  ☑ 
Ease of process   ☑ 
Low ost ☑  ☑ 
Support for r search/flex bility ☑ ☒  
Cl nical r levance 
 
☒ 
 
☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = dis ; ☑ = advantages. 
6 1. Flow Cyt ry 
Flow cytometry can be used for ch ract r zing tumor cell dissemination patterns and kinetics in 
preclinical mod ls of cancer metasta is [64]. Using flow cytometry in a preclinic l setting, human 
canc r cells can b  ef ectively identified among mouse leukocytes. This process has been described 
previous y by Allan et al. (2005) [73]. Briefly, flow cytometry can be used to identify CTCs based on 
th ir size, positive stai ing with a FITC-conjugated anti-hu an leukocyte gen (HLA) antibody, 
negative stai ing with a phycoerythrin (PE)-conj gated anti-mous  pan-leukocyte CD45 antibody, 
and aneuploidy DNA c ntent base  propidium io ide (PI) stai ing [64,73]. 
This CTC analy is a proach was one of the first to allow f r early d tection and quantification 
of are metas atic tumor cells in the blood of mice an  this led to evidence of CTC contribution to the 
development of m tas atic d sease [64]. Util zing the preclinical potential of flow cytometry analy is 
of CTCs, studies have as essed tu or cell dissemination patterns using spontaneous and 
experimental CTC/metasta is models [64] and tra ked the kin tics of CTC generation in ivo by 
analyzing multiple breast c cer c ll lines a d thei  relationship between CTC  and metasta is (see 
Figure 3a) [72]. 
Flow cyt metry is one of th  most cost-effective CTC enumeration techn logies available for 
preclinical CTC analy i , which allows for h rvesting of viable cells for downstre m analy is if a 
fluor scence ac vated cell sorting (FACS) instrument is used. However, this particular method of 
CTC enum ration relies heavily on expression of L  on the hu an tumor cells [73]. A  such, the 
use of cell lines with lower or absent levels of HLA expression may pr sent difficulties with this 
technique. This is particularly r levant when considering f ture a plication of this assay to 
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mice or NOD/SCID mice via the ma mary f t p d (MFP). At several time point  post-injection, mice 
w re sa rificed and blood (1 mL) and tissues w re collected and analyzed. CTC k netics in blood was 
easured by low cyto try (left pa el; mean ± SEM, n = 5 mice/group) and the incidence of lung 
metasta is (% of mice in the group) wa  measured a  a essed istopath logy (right pa el). Adapted 
from R f re ce [72]. (b) Human pros ate ca r cells of differing metas tic ability w r  injected into 
male nude mice via the right orsol teral lobe of the pros ate gland. A  several timepoints post 
injection, mic  w re sa rificed and blo d (100 µL) was col ected and split int  two 50 µL aliquots 
b fore an lysis using an adapted C llSearch® CT  assay to a ss CTC k netics b tween epithelial 
(LNCaP, C4-2B) versus m senchymal (PC-3M, PC-3) cell lines (left pa el, mean ± S M, n = 5–12 
ice group . To compar the diff r nce in CTC numb r d tect d using EMT-dep dent (EpCAM+) 
versus EMT semi-indep dent (EpCAM+/HLA+) ad pted C llSearch® a says in matched samples 
(right panel; m an ± SEM); positive valu s = more CTCs tected with EMT semi-indep dent assay, 
negative values = more CTCs d tecte  with EMT-dep dent assay. * = significant diff rence relative 
to PC-3; α = significant diff rence relative to LNCaP C4-2B; δ = significant diff rence relative to 
LNCaP (p ≤ .05). A apted fro  R f re ce [45]. (c) Human PC-3 pros at  can r cells (m senchymal 
phenotype) w r  injected into male nu e mice via the right dorsol teral l be of the pros ate gland. At 
several timepoints, post injection blood (100 µL) wa  serially collected and analyzed using the 
Par ortix™ CTC analy is platform. 
Table 2. Comparison of precl nical CTC analy is approaches. 
Feature Flow Cytometry C llSearch® Parsortix™ 
S nsit vity  ☑ ☑ 
Captur s cells i dep dent of phenotype ☒ ☒ ☑ 
Ability f r downstre m l i  ☑ ☒  
Accurat low bl d volume analysis ☒ ☑ ☑ 
Ease f process ☒  ☑ 
Low ost ☑  ☑ 
Supp t fo  r se r h/flex bility ☑ ☒ ☑ 
Cl nical r levance 
 
☒ 
 
☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = is dvantages; ☑ = dvantages. 
6 1. Flow Cytometry 
Flow cytomet y c n be used for ch racter zing tumor cell dissemi atio  patterns and kinetics in 
preclinical model  of ancer metasta is [64]. Using flow cytometry in a preclinical setting, human 
an er cells can b  effectively identified among mouse leukocytes. This process has been described 
previousl  by Allan et al. (2005) [73]. Briefly, flow cytometry can be used to identify TCs based on 
their size, positive stai ing with a FITC-conjugated anti-hu an leukocyte antigen (HLA) antibody, 
negative stai ing with a phycoerythrin (PE)-c njugated anti-mouse pan-leukocyte CD45 antibody, 
and aneuploidy DNA co tent base  ropidium o ide (PI) stai ing [64,73]. 
This TC analy is a proach was one of the first to allow fo  early d ectio  and quantif cation 
of ar  metas a ic tum r cells n the blo d of mice and this led to evid nce of TC contributi n to the 
d velopment of metas at c d s ase [64]. Util zing the preclinical po ential of flow cytometry analy is 
of TCs, tudies have as essed tumor cell disseminat on patterns using spo taneous and 
xperimental TC/metasta is models [64] and tracked the ki etics of TC generation in ivo by 
analyzing mu tiple brea t an r cell ines and th i  r lationship b tw en TCs and metasta is (see 
Figure 3a) [72]. 
Fl w cytometry is one o  the most cost-effective TC e umeration techn logies available for 
preclinical TC analysis, which allows for harvesting of viable cells for downstream analy is if a 
fluores nce activated cell sorting (FACS) instrument is used. However, this particular meth d of 
TC numerati  relies heavily on expressi n of HLA on t e hu an tumor cells [73]. A  suc , the 
use of cell lines with ower r absent lev l  f HLA expression may pr sent difficulties with this 
technique. This is p r icularly r levant when considering f ture a pl cati n of thi  assay to 
Ease f pro ss
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mice or NOD/SCID mice via the ma ary fat pad (MFP). At sev r l ti e points post-injection, mice 
were sacrificed and blood (1 mL) and ti sues were collecte  an  analyzed. CTC kin tics in blood was 
measured by flow cytometry (le t panel; an ± SEM, n = 5 mic /group) and th  i cidence of lung 
metastasis (% of mice in the group) w  measured as ass sed his pathology (right panel). A apted 
from Ref rence [72]. (b) Huma  prostate ancer cells f differi g eta t tic bility w r  i jected i to 
male nud  mice vi  t e right dorsol t ral lob  of th  prostate gland. At s veral timepoints post 
injection, mice were sacrificed and blo d (100 µL) wa  llected and split into two 50 µL aliqu ts 
before a alysis using an d pted CellSe ch® CTC assay to ssess TC kinetics b tween epitheli l 
(LNCaP, C4-2B) versus mesenchymal ( -3M, PC-3) c ll lines (l ft panel, mean ± SEM, n = 5–12 
mice/group). To co pare the differen  in CTC numb r det cted using EMT-dep ndent (EpCAM+) 
versus EMT semi-independent (EpCAM+/HLA+) adapte  C llSearch® assays in m tc e  amples 
(right panel; mean ± SEM); positive values = mor  CTCs detected with EMT se i-independent assay, 
negative values = more CTCs detected with EMT-d pen nt assay. * = significant differ c  relative 
to PC-3; α = significant difference relative to LNCaP C4-2B; δ = significant difference relative to 
LNCaP (p ≤ 0.05). Adapted from Reference [45]. (c) Hum  PC-3 prostat  cancer cells (mes chymal 
phenotype) were injected into male nude mic  via the right orsolateral lobe of th  prost t  land. At 
several timepoints, post injection blood (100 µL) wa  serially collecte  and analyzed using the 
Parsortix™ CTC analysis platform. 
Table 2. Compariso  of preclinical CTC analysis ap roaches. 
Feature Flow Cytometry CellSearch® Parsortix™ 
Sensitivity ☑ ☑☑  ☑  
Captures cells inde endent of phe oty e ☒   
Ability for downstream analysis ☑ ☒  
Accurate low blood volum  analysis   ☑ ☑ 
Ease of process ☒  ☑ 
Low cost ☑☑☑  ☑  
Support for research/flexibility ☑☑ ☒ ☑ ☑ 
Clinical relevance 
 
☒ 
 
☑☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = disadvantages; ☑ = advantages. 
6.1.1. Flow Cytomet y 
Flow cytometry can be used fo  ch ra terizing tumo  cell issemin tion patterns a d ki tic  in 
preclinical models of cancer meta tasis [64]. Using flow yto etry in a precli ical setting, hu an 
cancer cells can be effectively identified among mous  leukoc t s. This process ha  b en des ribed 
previously by Allan et al. (2005) [73]. Briefl , flow cytometr  can be us d to identify CTCs based on 
their size, positive staining wit  a FITC-conjugat d anti-human leukocyte a tigen (HLA) antibody, 
negative staining with a phyco rythrin (PE)-conjugated nti-m use pan-leuk yte CD45 antib dy, 
and aneuploidy DNA content base  propidium iodide (PI) staining [64,73]. 
This CTC analysis approach was one of the first to all w for early d t ction and qu ntificati n 
of rare metastatic tumor cells in the blo d of mice and this led to vidence f CTC contribution to th  
development of m tastatic diseas  [64]. Utilizing the preclinic l pot ntial of flow cytom try nalysis 
of CTCs, studies have assessed tumor cell di semin tion patterns using ponta e us and 
experimental CTC/metastasis models [64] nd track d the kinetic  of CTC generati n in vivo by 
analyzing multiple breast cancer c ll lines and thei  r l tio ship betw e  CTCs and m t stasi  (se  
Figure 3a) [72]. 
Flow cytometry is one of th  m st ost-effective CTC numeration tech ologies available f  
preclinical CTC analysis, which allow  for harvesting of viable cell  f  down tr am analysis if a 
fluorescence activated cell sorting (FACS) instrument is used. However, thi  particular method f 
CTC enumeration reli s heavily on expression f HLA on the human tum r cells [73]. s such, the 
use of cell lines with lower or absent l v ls f HLA expr s i n may pr nt difficulti s with this 
technique. This is particularly r lev nt w en considering futu  pplication f this assay to 
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mice or NOD/SCID mice via the mammary fat pad (MFP). At several time points post-injection, mice 
ere sacrificed nd blood (1 mL) and tissues were co le te  and analyzed. CTC kinetics in blood was 
easured by flow cyto try (left a el; ean ± SEM n = 5 mic /group  and the incidence of lung 
me ast sis (% of mice in the group) was measured as asse sed histopathology (right pa el). Adapted 
from R ference [72]. (b) Human prostate cancer ce ls of differing metastatic ability were injected into 
male nude ice via the right orsola era  l be of the prosta e gland. At several timepoints post 
injection, mice were sacrificed an  blood (100 µL) was coll ct d and split into two 50 µL aliquots 
before analysis using an adapted CellSearch® CT  assay to assess CTC kinetics between epithelial 
(LNCaP, C4-2B) versus mesenchy al (P -3M, PC-3) c ll lines (left panel, mean ± SEM, n = 5–12 
m ce/group). To compare the diff r nce in TC number detect d using EMT-dependent (EpCAM+) 
ersu  EMT se i-in pendent (Ep AM+/HLA+) adapted CellSearch® assays in matched samples 
(right panel; mean ± SEM); positive values = more CTCs etected with EMT semi-independent assay, 
n gative values = more CTCs detected wi h EMT-dependent assay. * = significant difference relative 
to PC-3; α = signi icant difference relativ  to LNCaP C4-2B; δ = significant difference relative to 
LNCaP (p ≤ 0.05). Adapte  fro  Reference [45]. (c) Human PC-3 prostate cancer cells (mesenchymal 
phenotype) were inject d into male nu e m ce via the right dorsolateral lobe of the prostate gland. At 
several timepoints, post injection blood (100 µL) was serially collected and analyzed using the 
Parsortix™ CTC anal sis platform. 
Table 2. Compariso  of reclinical CTC analysis approaches. 
Feature Flow Cytometry CellSearch® Parsortix™ 
S sitivity  ☑☑  
Captu s cells indepe dent of phenotype   ☑ 
bi ity f r down tream l i   ☒  
Accurate low bl od volume analysis  ☑  
Ease of process   ☑ 
Low ost ☑☑  ☑☑ 
Support for research/flexibility  ☒  
Clinical relevance 
 
☒ 
 
☑☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = disadvant g s; ☑ = adva tag . 
6.1.1. Flow Cyto etry 
Flow cyto etry can be used for charact rizing tumor cell dissemination patterns and kinetics in 
preclinic l models of cancer metastasi  [64]. Using flow cytometry in a preclinical setting, human 
cancer c lls can be effectively identified among mouse leukocytes. This process has been described 
previously by Allan et al. (2005) [73]. Briefly, flow cytometry can be used to identify CTCs based on 
their size, positive staining with a FITC-conjugated anti-hu an leukocyte antigen (HLA) antibody, 
n gative staining with a phycoerythrin (PE)-conjugated anti-mouse pan-leukocyte CD45 antibody, 
and aneuploidy DNA content bas d propidium iodi e (PI) staining [64,73]. 
This CTC an lysis approach was one of the first to allow f r early detection and quantification 
of rare metastatic tumor ells in the blood of mice and this led to evidence of CTC contribution to the 
development of metastatic disease [64]. Utilizing the preclinical potential of flow cytometry analysis 
of CTCs, stu ies have assessed tumor cell dissemination patterns using spontaneous and 
experim ntal CTC/metastasis models [64] and tracked the kinetics of CTC generation in vivo by 
analyzing multiple breast cancer cell lines and their relationship between CTCs and metastasis (see 
Figure 3a) [72]. 
Flow cytom try is one of the most cost-effective CTC enumeration technologies available for 
preclinical CTC analysi , which allows for harvesting of viable cells for downstream analysis if a 
fluorescence activated cell sorting (FACS) instrument is u ed. However, this particular method of 
CTC enumeration reli s heavily on expression of L  on the hu an tumor cells [73]. As such, the 
use of cell lin s with lower or absent levels of HLA expression may present difficulties with this 
technique. This is particularly relevant when considering future application of this assay to 
Low cost
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mice or NOD/SCID mice via the mammary fat pad (MFP). At several time points post-injection, mice 
were sacrificed and blood (1 mL) and tissues were collected and analyzed. CTC kinetics in blood was 
measured by flow cytometry (left panel; mean ± SEM, n = 5 mice/group) and the incidence of lung 
metast sis (% of mic  in the group) was easured as assessed histopathology (right panel). A apted 
fro  R ference [72]. (b) Human prostate cancer cells of differing metastatic ability were inje ted into 
male nude mice via the right dorsolateral lobe of the prostate gland. At everal timepoints post 
injection, mice were sacrificed and blood (100 µL) was collecte  nd split nto two 50 µL aliquots 
before analysis using an adapted CellS arch® TC as ay to assess CTC kinetics between epithelial 
(LNCaP, C4-2B) versus mesenchymal (PC-3M, PC-3) cell lines (left panel, m an ± SEM, n = 5–12 
mice/group). To compare the difference in CTC number det cte  using E T-dependent (EpC M+) 
versus EMT semi-independent (Ep AM+/HLA+) adapted CellSearch® ssays in matched samples 
(right pa el; mean ± SEM); positive v lues = more CTCs detected with EMT sem -independent assay, 
negative values = more CTCs detected with EMT-d penden  assay. * = significant difference relative 
to PC-3; α = significant difference relative to LNCaP C4-2B; δ = significant difference relative to 
LNCaP (p ≤ 0.05). Adapted from Reference [45]. (c) Human P -3 pro tate cancer cells (mesenchymal 
phenotype) were injected into male nude mice via the right dorsolateral lobe of the prostate gland. At 
several timepoints, post injection blood (100 µL) was serially collected and analyzed us ng the 
Parsortix™ CTC analysis platform. 
Table 2. Co p r son of preclinic l CTC a alysis approaches. 
Feature Flow Cytometry CellSearch® Parsortix™ 
Sensitivity ☑ ☑☑  ☑☑  
Captures cells indepen ent of phe otype ☒ ☒  
Ability for downstream analysis ☑ ☒ ☑☑  
Accurate low blo d v lume analysis ☒ ☑ ☑☑☑ 
Ease of process ☒ ☒  
Low cost ☑☑☑ ☒ ☑☑ 
Support for research/flexibility ☑☑ ☒ ☑☑☑ 
Clinical relevance 
 
☒ 
 
☑☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = disadvantages; ☑ = advantages.
6.1.1. Flow Cyt metry 
Flow cyt metry can be used for characterizing tumor cell disseminati  patter s and kinetics in 
preclinical models of cancer metastasis [64]. Usi g flow cytometry in a preclinical setting, h an 
cancer cells can be effectively ide tified among mouse leukocytes. This rocess has been described 
previously by Allan et al. (2005) [73]. Briefly, fl w c tometry can be used t  identify CTCs based o  
their size, positive staining with a FITC-conjugated anti-human leukocyte antigen (HLA) antibody, 
negative stai ing with a hyc erythrin (PE)-co jugated anti-mouse pan-leukocyte CD45 antibod , 
and aneuploidy DNA content base  propidium io i e (PI) staining [64,73]. 
This CTC analysis approach was one of the first to allow for early detectio  a d quantificati  
of rare metastatic tumor cells i  the blood of ice and this led to evidence of  co tributio  to the 
development of metastatic disease [64]. Utilizing the preclinical potential of flow cytometry analysis 
of CTCs, studies have assessed tumor cell disse i ati n patterns using sponta e us and 
experimental CTC/metastasis models [64] and tracked the kinetics of CTC generation in i o y 
analyzing multiple breast cancer cell lines and their relationship bet ee  TCs and etastasis (see 
Figure 3a) [72]. 
Flow cytometry is one of the most cost-effective CTC enumeratio  tech l gies available f r 
precli ical CTC analysis, which allows for harvesting of viable cells f r do nstream analysis if a 
fluorescence activated cell sorting (FACS) instrument is used. However, this particular method of 
CTC enumeration relies heavily on expression of HLA on the human tumor cells [73]. As such, the 
use of cell lines with lower or absent levels of HLA expression may present difficulties with this 
technique. This is particularly relevant when considering future application of this assay to 
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ice or NOD/SCID mice via the ma mary fat pa  (MFP). At several time points post-injection, mice 
w re sacrificed and blood (1 mL) and tissues w re collected and analyzed. CTC kinetics in blood as 
measured by flow cytometry (left panel; mean ± SEM, n = 5 mice/group) and the incidence of l ng 
etast is (% of mice in the group) was measured as as essed histopath logy (right panel). Adapted 
from R f rence [72]. (b) Human pros ate cancer cells of differing metas atic ability w re injected into 
male nud  mice via the right dorsolateral lobe of the pros ate gland. At several ti epoints post 
injection, mice w re sacrificed and blood (100 µL) was coll cted and plit into two 50 µL aliquots 
bef re analysis using an adapted CellSearch® CTC assay to as ess CTC kinetics between epithelial 
(LN aP, C4-2B) versus m s nchymal (PC-3M, PC-3) ell lines (left pa el, mean ± SEM, n = 5–12 
mice/group). To compare the diff rence in CTC number detected using EMT-dependent (EpCAM+) 
ve sus EMT semi-independent (EpCAM+/HLA+) adapted CellSearch® assays in matched samples 
(right pan l; mean ± SEM); positive values = more CTCs d tected with EMT semi-independent assay, 
negative values = mor  CTCs d tected with EMT- epe dent assay. * = significa t diff rence relative 
to PC-3; α = significant diff rence relative to LNCaP C4-2B; δ = significant diff rence relative to 
LNCaP (p ≤ .05). Adapted from R f ence [45]. (c) Human PC-3 pro te cancer cells (m senchymal 
phenotype) w re injected into male nude mice via the right dorsolateral lobe of the pros ate gland. At 
several timepoints, post injection blood (100 µL) a  serially collected and analyzed using the 
Parsortix™ CTC analy i  platf rm. 
Table 2. Co p rison of cl nic CTC a aly is ap roaches. 
F ature Flow Cytometry CellSearch® Parsortix™ 
Sensit vity    
Captures cells independent of phenotype ☒   
Ability for downstream analy is ☑  ☑ 
Accurate low blood volume analysis ☒  ☑ 
Ease of process ☒  ☑ 
Low cost ☑ ☒ ☑ 
Support for r search/flex bility ☑ ☒ ☑ 
Cl nical r levance 
 
☒ 
 
☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = disadvantag s; ☑ = advantages. 
6 1. Flow Cytometry 
Flow cytometry can be used for ch racter zing tumor cell disseminati  patterns and ki etics in 
preclinical models of cancer metasta is [64]. Using flow cyt etry in a preclinical setting, h an 
cancer cells can b  effectively ide tified among mouse leukocytes. This rocess has been described 
previously by Allan et al. (2005) [73]. Briefly, fl w c t metry can be use  t  ide tify CTCs based  
their size, positive stai ing with a FITC-conjugated anti-hu an leukocyte antige  (HLA) antibody, 
negative stai ing with a hyc erythrin (PE)-conjugated a ti-mouse pan-leukocyte CD45 antibody, 
and aneuploidy DNA content based propidium io i e (PI) stai ing [64,73]. 
This CTC analy is a proach was o e of the first to allow f r early d tectio  and qua tificatio  
of are metas atic tumor cells in the blood of ice and this le  to evidence of CTC contributio  to the 
development of metas atic disease [64]. Util zing the preclinical potential of flow cytometry analy is 
of CTCs, studies have as essed tu or cell disse i ati n patterns usi g sponta eous and 
experimental TC/metasta is models [64] and tracked the kinetics of CTC generation in ivo by 
analyzing multiple breast cancer cell lines a d thei  relatio ship between CTCs and metasta is (see 
Figure 3a) [72]. 
Flow cytometry is one f the most cost-effective CTC enumeration techn l gies available for 
preclinical CTC analy is, w ich allows for harvesti g of viable cells for do stream analy is if a 
fluorescence activated cell sorting (FACS) instrument is used. However, this particular method of 
CTC enumeration relies heavily on expression of HLA on the human tumor cells [73]. A  such, the 
use of cell lines with lower or absent levels of HLA expression may pr sent difficulties with this 
technique. This is particularly r levant when considering f ture a plication of this assay to 
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mice or NOD/SCID mice via the ma mary f t pad (MFP). At several time point  post-injection, ice 
w re sa rificed and blood (1 mL) and tissues w re collected and analyzed. CTC k netics in blood was 
measured by flow cytometry (left panel; mean ± SEM, n = 5 mice/group) and the incidence of lung 
metasta is (% of mice in the group) was measured a  a ess d histopath logy (right panel). Adapted 
from R f rence [72]. (b) Human pros ate can r cells of differing metas tic ability w r  injected into 
male ude mice via th  right dorsol teral lob  of the pros ate gland. At several timepoints post 
injection, mic  w re s rificed and blood (100 µL) w s collected and split into two 50 µL aliquots 
b fore an ysis using an adapt d C llSearch® C C assay to a ess CTC k netics b tween epithelial 
(LNCaP, C4-2B) versus mesenchymal (PC-3M, PC-3) cell lin s (left p nel, mean ± SEM, n = 5–12 
mice/group). To compar the diff rence n C C numb  d tected using EMT-de dent (EpCAM+) 
versus EMT semi-indep de t (EpCAM+/HLA+) adapted C llSearch® assays in matched samples 
(right panel; mean ± SEM); p sitive v ues = mor  CTCs d tecte  with EMT semi-indep de t assay, 
negative values = mo e CTCs d cted with EMT-dep dent s ay. * = significant diff rence relative 
to PC-3; α = significant diff rence relative to LNCaP C4-2B; δ = significant diff rence relative to 
LNCaP (p ≤ .05). Adapted fr  R f re ce [45]. (c) Human PC-3 pros ate can r cells (m senchymal 
phenotype) w r  injected into ale nude mice via the right dorsol teral l be of the pros ate gland. At 
several timepoints, post injection blood (100 µL) wa  serially collected and analyzed using the 
Parsortix™ CTC analy s platform. 
Table 2. Comp ri on of p cl nic l CTC a aly is a proaches. 
Feature Flow Cytometry C llSearch® Parsortix™ 
Se si vity ☑ ☑  
Captur s cells indep dent of phenotype ☒  
Ability f r downstre m analy is ☑  ☑ 
Accurate low blood volume analysis ☒   
Eas  of process ☒ ☒  
Low cost ☑   
Supp t for r search/flex bility ☑ ☒ ☑ 
Cl nical r levance 
 
☒ 
 
☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = is dvantages; ☑ = dvantages.
6 1. Flow Cytometry 
Flow cytometry ca  be used for ch racter zing tumor cell disseminati  patterns and ki etics in 
preclinical models of ancer metasta is [64]. Using flow cyt metry i a preclinical setting, human 
an r cells ca  b  effectively i e tified among mouse le kocytes. This rocess has been described 
previousl  by Allan et al. (2005) [73]. Briefly, flow c t metry can be used t  identif  TCs based on 
their size, positive stai ing wit a FITC-conjugate  anti-hu an leukocyte antige  (HLA) antibody, 
negative stai ing with a phyc erythrin (PE)-conjugated anti-m use pa -leukoc te CD45 a tib dy, 
and aneuploidy DNA co tent based r pidium o ide (PI) stai ing [64,73]. 
This T  analy is a proach was o e of the first to allow f  early d tectio  and quantif cati n 
of ar  metas atic tumor cells i the blo d of mice and this le  to evid nce of CTC contributi n to the 
development of metas at c dis ase [64]. Util zing the preclinical potential of flow cytometry analy is 
of TCs, studies have as essed tum r cell dissemi ati n patterns using sp ta eous and 
xperimental TC/metasta is models [64] and tracked t e kinetics of TC generatio  in ivo by 
analyzi g mu tiple breast an r cell lines and thei  relatio ship b twee  TCs and metasta is (see 
Figure 3a) [72]. 
Flow cytometry is one of the most c st-effective TC enu eration techn logies available for 
preclinical TC a aly is, w ich allows for harvesting of viable cells for dow stream analy is if a 
fluores nce activated cell sorting (FACS) instrument is used. However, this particular meth d of 
TC enumeration relies heavily on expressi n of HLA on t e human tumor cells [73]. A  suc , the 
use of cell lines with lower or absent levels of HLA expression may pr sent difficulties with this 
technique. This is particularly r levant when considering f ture a pl cati n of thi  assay to 
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mice or NOD/SCID mice via the mammary f t pad (MFP). At several time points post-injection, mice 
w re s r fi d nd blood (1 L) and tissues were coll cted a d analyz d. CTC k n tics in blood was 
easured y flo  cyt m t y (left panel; me  ± SEM, n = 5 m /gr up) and the incidence of lung 
metastasis % of ic  in the grou ) was measured as s ess histop thology (ri ht nel). Adapted 
from Reference [72]. (b) H m n pros at  cancer cells f d fferin  m t static bility were injected into 
male n de mice via he ight dor lateral lobe f the p os at  gland. At several timepoints post 
jec ion, mice wer  sacrifice and bl od (100 µL) was coll ct d and s li  i t  wo 50 µL aliquots 
before analysis using an ad pted CellS ar h® CTC as ay to ass ss CTC kinetic  between epithelial 
(LNC P, 4-2B) versus mesenchym l (PC-3M, P -3) c ll l nes (l ft pa l, an ± SEM, n = 5–12 
mice/group). To compa e the differ n  in CTC number d t cted using EMT-dependent (EpCAM+) 
versus EMT semi-i d pe dent (EpCAM+/HLA+) adapte  C llS arch® assays in matched samples 
(r ght a el; mean ± SEM); positive values = mor  CTC  detecte  it  EMT e i-independent assay, 
negative valu s = more CTCs d tecte  wi h EMT-dependent assay. * = signific nt difference rel tive 
to PC-3; α = significant differ nce r lative to LNCaP C4-2B; δ = sig i ic nt d ff rence relative to 
LNCaP (p ≤ 0.05). A apted from Reference [45]. (c) Human PC-3 prostat  cancer cells (mesenchymal 
phenotype) w r  inject d into male nude mice via the right orso teral lobe of the prostate gland. At 
s v ral t epoints, post inj ctio blo  (100 µL) was serially collected and analyzed usi g the 
Parsort x™ CTC analysis platform. 
Table 2. Compari o  of r cli ical CTC analysis approaches. 
Feature Flow Cytometry CellSearch® Parsortix™ 
Sensitivity ☑ ☑☑☑ ☑  
Cap ures cells independent of phenotype ☒  ☑ 
Ability for d wnstream analysis ☑   
Ac urate low blood volume analysis   ☑  
E e of process ☒  ☑ 
Low cost ☑☑☑ ☒ ☑☑ 
Support for research/flexibility ☑  ☑  
Clinical relevance 
 
 
 
☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = disadvantages; ☑ = t . 
6.1.1. Flow Cytometry 
Flow cytometry can be used for characterizing tumor cell dissemination patterns and kinetics in 
p eclinical mo els of cancer m tastasis [64]. U ing flow cytom try i  a pre linical setting, hum n 
can er lls can be ffectively id tified among mouse leuko ytes. This pr cess h s been described 
pr viousl  by Allan t al. (2005) [73]. Briefly, flow cytomet y can be us  to identify CTCs based on 
th ir size, positiv  staining with a FITC-conjug ted anti-human leukocyte ntigen (HLA) tibody, 
neg tive staini g with a phycoerythri  (PE)-co j gated anti-mo se pan-leukocyt  CD45 antibody, 
and aneuploid  DNA content based pr pidium io ide (PI) staining [64,73]. 
This CTC nalysis a proach was one of the first to allow for early detection and quantification 
of rare met static tu r c lls in the bl od f ice and this led to evi ence of CTC co tribution to the 
developm nt of metastatic dise s  [64]. Utilizing the pr linical p te tial of flow cytometry analysis 
of CTCs, studi  have assess d tumor cell disse inati n patt rns usi g pontaneous and 
experim nt l CTC/ etastasis mo el  [64] and tracked the ki eti s of CTC g eration in vivo by 
analyzing multiple breast cance  c ll lin s d th ir relatio ship between CTCs and metastasi  (see 
Figure 3a) [72]. 
Flow cytometry is one f the most cost-eff ctive CTC enumeration technologies available for 
preclinical CTC analysis, which allows for harvesting f vi ble cell  for downstream analysis if  
fluorescence activ t d cell so ting (FACS) instru nt is used. However, this p rticular method of 
CTC numeratio  relies h avily on xpression of HLA on t e human tu or cells [73]. As such, the 
use of cell lines with lower r absent lev ls of HLA expression may present difficulties with this 
tec nique. This is particularly rel vant whe  conside ing fut re application of this assay to 
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ice or NOD/SCID mice via th ma ary fat d (MFP) At s v ral time points po t-injection, mice 
were acrificed and blood (1 mL) and tissues were ollecte and analyzed. CTC kinetics in blood was 
m asur d by flow cytometry (l ft anel; mean ± SEM,  = 5 m ce/group) an  the incidence of lung 
metast i  (% of mic  in t  group) was measured s sessed h stopathology (righ  panel). Adapted 
f m R f  [72]. (b) Human prostate ancer cel s f differing metastatic ability were injected into 
male nude mice via the right dorsol teral lobe of the rosta  glan . At several timepoints post 
injectio , mice ere sa rific   blood (100 µL) was co lected and split in o two 50 µL aliquots 
b for  analysis u ing  adapt d ellSear h® CTC ass y to assess CTC kinetics between epithelial 
(LNCaP, C4-2B) versus mes nchym  (PC-3M, PC-3) cell lines (l ft panel, mean ± SEM, n = 5–12 
ice/group). To co pare th  differe ce in CTC umber detected using EMT-de endent (EpCAM+) 
versus EMT semi-ind p nd t (EpCAM+/HLA+) adapted C llSearch® assays in matched samples 
(right panel; mean ± SEM); posit ve valu  = ore CTCs e ected with EMT semi-in ependent assay, 
n g ive v ues = more CTCs detected with EMT-d enden  assay. * = significant difference relative 
to P -3; α = significant differen e relat ve o LNCaP C4-2B; δ = significa t difference relative to 
LNCaP (p ≤ 0.05). Adapted from Ref re [45]. (c) Human PC-3 prostate cancer cells (mesenchymal 
phenotype) wer injected int  male nud  mice via he right orsolateral lobe of the prostate gland. At 
several timep ints, post injecti n b od (100 µL) w  er all  collected and analyzed using the 
Parsortix™ CTC analysis platform. 
ab  2. Com a ison of pr clinical CTC analysis approaches. 
Feature Fl w Cytometry CellSearch® Parsortix™ 
Sensitivity ☑ ☑ ☑☑☑ 
Cap ur s cells in ependent of phenotype ☒ ☒ ☑ 
Ability for downstream analysis ☑ ☒ ☑☑☑ 
Accurate low blo d v lume analysis ☒   
Ease f pr cess ☒ ☒  
Low cost  ☒  
Support for research/flexibility ☒ ☑☑☑ 
Clinical relevance 
 
☒ 
 
☑☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = dis dvantages; ☑ = advantages. 
6.1.1. F o  Cyto etry
Flow cyto etry can b  used for characterizi g t mor cell d s eminatio  patterns and kinetics in 
pr cl n cal models of ca cer tastasi [64]. Using flow cyto etr  i  a precli ical setting, human 
ca c r c lls ca  e effectiv l  ide tified am ng ous  l uk cyt s. This proces  has been described 
previously by Al a  e  al. (2005) [73]. Briefly, fl w c t metry c  be use  to identify CTCs based on 
their size, p sitiv  st i ing with a FITC- o ju at d a ti- uman leukocyte a tigen (HLA) a tibody, 
negative staini  with a phycoeryt ri  (PE)-c njugated ti-mouse pan-leuk c te CD45 antibody, 
an  aneu lo y DNA cont n  b se propidium i i e (PI) stai i  [64,73]. 
This CT  a alysi  pproach w s ne of the first t  allow for early detection a d qua tification 
of rare metastatic tumor cells in the blood f mice a  his led to evi ence of TC contribution to the 
ev lopment of m tastat c d sease [64]. Uti izing the preclinic l potential of flow cytometry analysis 
of CTCs, studies hav  assessed umor cell dis emin tio patter s using sp ntaneous and 
ex rimental C /metas a is models [64] and tracked the ki etics of CT  ge eration i  vivo by 
analyzi g mul ipl breast cancer cell lin s an  their relation h p b tween CTCs an  metastasis (see 
Figu e 3a) [72]. 
Fl  cy om try s ne of th  st cost-effectiv  CTC enum ration technologies available for 
preclinical C C a alysis, hich allows for arvesting of vi ble cells for downstream analysis if a 
fluoresc nce activat d cell orting (FACS) nstrument is used. However, this particular method of 
CTC enum ration relies heavily on expression of HLA on th  uman tumor cells [73]. As such, the 
u  of cel  lines with low r or absent lev ls of HLA expr sion may pre ent difficulties with this 
technique. T is is particularly relevant whe  considering fu ure application of this assay to 
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mice r NOD/SCID mic  ia th a mary fat ad (MFP). At s v ral t me p ints post-injection, mice 
w r  acrifi ed and blood (1 mL) and tissues w re ollecte nd analyzed. CTC kinetics in blood was 
m asur d by flow cyt etry (left el; mean ± SEM, n = 5 mice/group) and the incidence of lung 
metast i  (% of mic  in t e group) was measured s as esse  histopath logy (right panel). A apted 
from R f n  [72]. (b) Human pros ate canc r cells of iffering metas atic ability w re injected into 
male nude mic  via he ri ht orsolateral obe of the r a e gland. At several timepoints post 
i jection, mic re sacrific   blood (100 µL) w s co le ted and split into two 50 µL aliquots 
b for  analysis using an adapted ellSear h® CTC ssay to as ss CTC kinetics between epithelial 
(LNC P, C4-2B) versus m s hym l (PC-3M, PC-3) cell lin s (left panel, mean ± SEM, n = 5–12 
m ce/group). To compar  th  diff renc  in CTC umber tecte using EMT-dependent (EpCAM+) 
versus E T s mi-ind pendent (Ep AM+/HLA+) adapted C llSearch® assay  in matched samples 
(right pan l; m an ± SEM); posit v valu  = m r  CTC  d ed with EMT semi-independent assay, 
n ga ive values = ore CTC  d tected with EMT-d penden  assay. * = signif cant diff rence relative 
to PC-3; α = significant diff re ce rel tive to LNC P C4-2B; δ = significant diff rence relative to 
LNCaP (  ≤ .05). Adapted f m R f e  [45]. (c) Human PC-3 pros ate c cer cells (m senchymal 
pheno ype) w  injected in  male nud  mice via he right orsol teral lobe of the pros ate gland. At 
several timepoints, p st injecti n blo  (100 µL) wa  eriall  collected and analyzed using the 
Parsortix™ CTC analy is platform. 
ble 2. Com a ison of precl nical CTC analy is approaches. 
F ature Fl w Cytometry CellSearch® Parsortix™ 
Sensit vity ☑ ☑ ☑ 
Captures cells independent of phenotype ☒ ☒ ☑ 
Ability for downstrea  analy is ☑ ☒ ☑ 
Accurate low blood volume analysis ☒ ☑  
Ease of process ☒ ☒  
Low cost ☑ ☒  
Support for r search/flex bility ☑ ☒ ☑ 
Cl nical r levance 
 
☒ 
 
☑
(FDA) 
☑ 
(CE Mark) 
☒ = dis dvantages; ☑ = dvantages. 
6 1. Flo  Cyto etry
Flow cytometry can b  u ed for ch racter zi g t mor cell d s emination patter s and kinetics in 
precl cal m dels f ca cer tasta is [64]. Using flow cyt etry in a pr clinical setti g, human 
ca c r cells ca   ff ctively ident fied am g mous leukocyt s. This process has been described 
previ usly by Allan e  al. (2005) [73]. Briefly, fl w c t metry ca  be used to identify CTCs based on 
their size, positive s i ing with a FITC-co ju at d a ti-human leukocyte a tige  (HLA) a tibody, 
negative stai i  with a phycoeryt ri  (PE)-conjugated ti-mouse pan-leuk c te CD45 antibody, 
and aneu lo y DNA conte  base propidium io ide (PI) stai ing [64,73]. 
This CT  analysis pr a h w s one of the first to allow for early d tection and quantification 
of are etas atic tumor cells i  th  blo d f mi e a d h s led to vi e ce of TC contribution to the 
developme t of m tas at c disease [64]. Util zi g the p ecli ic l potenti l of flow cytometry analy is 
of CTC , tu ie  have as essed umor cell di seminatio patter s using spontaneous and 
expe iment l CTC/metas a is models [64] and tracked the ki etics of CTC ge eration i  ivo by 
analyzi g mul ipl breast cancer cell lin s an  thei  rela ionsh p b tween CTCs and metasta is (see 
Figure 3a) [72]. 
Fl  cy om try is ne of th  m s ost-effe tiv  CTC umer tion tec n logies available for 
preclinical C C a aly is, hich allows f r arvesting of viable cells for downstream analy is if a 
fluoresce ce activa d c ll s rting (F CS) nstr e t is use . However, this particular method of 
CTC enumeration relies avily o expression of HL  on t e u an tumor cells [73]. A  such, the 
u of cell lines with low r or abse t lev ls o  HLA ex ression may pr sent difficulties with this 
technique. T is is pa ticularly r levant whe  considering f ure a plication of this assay to 
S pport f r r s arch/flexibility
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mice or NOD/SCID ice via the mammary fat pa  (MFP). At several time points post-injection, mice 
were sacrificed and blood (1 mL) and tissues were collecte  an  analyzed. CTC kinetics in blood was 
measured by flow cyto etry (left panel; mean ± SEM, n = 5 mice/group) and the incidence of lung 
metastasis (% of mice in the group) was easured as assessed histopathology (right panel). A apted 
fro  Reference [72]. (b) Human prostate cancer cells of differing metastatic ability were injected into 
male nude mice via the right dorsolateral lobe of the prostate glan . At several timepoints post 
injection, mice were sacrifice  and blood (100 µL) was collecte  and split into two 50 µL aliquots 
before analysis using an adapted CellSearch® C assay to assess C C kinetics between epithelial 
(LNCaP, C4-2B) versus mesenchy al (PC-3M, PC-3) cell lines (left pa el, mean ± SEM, n = 5–12 
mice/group). o compare the ifference in CTC nu ber etecte  using EMT-dependent (EpCAM+) 
versus EMT semi-independent (EpCAM+/HLA+) adapte  CellSearch® assays in matched samples 
(right panel; mean ± SEM); positive values = ore CTCs detected with EMT semi-in ependent assay, 
negative values = more CTCs detected with EM -dependent assay. * = significant ifference relative 
to P -3; α = significant difference relative to LNCaP C4-2B; δ = significant difference relative to 
LNCaP (p ≤ 0.05). Adapted from Reference [45]. (c) Human PC-3 prostate cancer cells (mesenchymal 
phenotype) were inject d into male nude mice via the right dorsolateral lobe of the prostate gland. At 
several timepoints, post injection blood (100 µL) was serially collected and anal zed using t e
Parsortix™ CTC analysis platform. 
Ta  2. C parison f pr clin  CTC al sis appro ches. 
Feature Flow Cytometry CellSearch® Parsortix™ 
Sensitivity ☑ ☑☑  ☑☑☑ 
Captures cells in ependent of phenotype ☒ ☒ ☑ 
Ability for d wnstrea  analysis ☑ ☒ ☑ ☑ 
Accurate low blo d v lume analysis ☒  ☑☑☑ 
Ease f pr e s ☒ ☒  
L w cost  ☒  
Support for research/flexibility ☑☑ ☒ ☑☑☑ 
Clinical relevance 
 
☒ 
 
☑☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = dis dvan ages; ☑ = dvantages. 
6.1.1. Flow Cytometry 
Flow cytometry can be used for c ar c erizi g tumor cell diss mi tion pa ter  a kine s in 
preclinical mo els of canc r met stasis [64]. Using flow cy o etr  in a recli ical setting, human 
cancer cells can be effectively ide tified am ng mou e leuk cytes. Thi pr cess s been des r b d
previously by Allan et l. (2005) [73]. B i fly, f ow yt try can b  use  t  id ntify CTC  based n 
th ir size, positiv  s ining wi h a FITC-conjug t d anti-huma  leukocyt  a t en (HLA) tib d ,
negative taining with a phycoerythrin (PE)- njugat d a ti-mou  pa -le ko yte CD45 a tib dy, 
and aneuploidy DNA con ent base  ropidium i ide (PI) st ining [64,73].
Th s CTC an lysis pproa h w s o  of the f rst to ll w for ear y d ction qu fication 
of rare etastatic tumor cells in the blood of mice and this led to evidence of CTC contribution to the 
development of etastatic disease [64]. Utilizing precli i al po ential f flow cy ome ry a a ysis 
of CTCs, studies have ssessed tu or cell disseminati n p tterns using spo tane us and 
expe imental CTC/metastasis model  [64] a d acke  th  kine cs of T  gene atio  in viv  by 
analyzi g ultiple brea t canc r cell lin s nd heir r lation h p between CTCs and e a tasis ( e 
Figure 3a) [72]. 
Flow cytom ry is on  of h  m s  ost-effective CTC enumerati  ech ologies av l ble for 
preclinical CTC analysis, which allows for harvesting of viable cells for downstream analysis if a 
fluorescence activated cell sorting (FACS) instrument is used. However, this particular method of 
CTC enumeration relies heavily on expression of HLA on the hu an tumor cells [73]. As such, the 
use of cell lines with lower or absent levels of HLA expression may present difficulties with this 
technique. This is particularly relevant when considering future application of this assay to 
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mice or NOD/SCID ice via the a mary fat pa  (MFP). At several time points post-injection, mice 
w re sacrificed and blood (1 mL) and tissues w re collecte  an  analyzed. CTC kinetics in blood was 
measured by flow cytometry (left panel; mean ± SEM, n = 5 mice/group) and the incidence of lung 
metasta is (% of mice in the group) was easured as as essed histopath logy (right panel). A apted 
from R f rence [72]. (b) Hu an pros ate cancer cells of differing metas atic ability w re injected into 
male nude mice via the right orsolateral lobe of the pros ate glan . At several ti epoints post 
injection, mice w re sacrifice  and blood (100 µL) was collected and split into t o 50 µL aliquots 
before analysis using an adapted CellSearch® TC assay to as ess CTC kinetics between epithelial 
(LNCaP, C4-2B) versus m senchymal (PC-3M, P -3) cell lines (left pa el, mean ± SEM, n = 5–12 
mice/group). To compare the diff rence in C C nu ber tected using EMT-dependent (EpCAM+) 
versus EMT semi-independent (EpCAM+/HLA+) adapte  CellSearch® assays in matched samples 
(right panel; mean ± SEM); p sitive values = ore CTCs d tecte  with EMT semi-in ependent assay, 
negative values = more CTCs d tected with EM -dependent assay. * = significant diff rence relative 
to P -3; α = significant diff rence relative to LNCaP C4-2B; δ = signific nt diff rence relative to 
LNCaP (p ≤ .05). Adapted from R f rence [45]. (c) Human PC-3 pros ate cancer cells (m senchymal 
phenotype) w re injected into male nude mice via the right dorsolateral lob  of the pros ate gland. At 
several timepoints, post injection blood (100 µL) wa  serially collected and analyzed using the 
Parsortix™ CTC analy is platform. 
Table 2. Co parison f prec ni a  CTC a al is ppr ach s. 
Fe ture Fl w Cyt metry CellSearch® Parsortix™ 
Sensit vi y ☑ ☑ ☑ 
Captures cells in ependent of phenotype ☒ ☒ ☑ 
Ability for d nstrea  analy is ☑  ☑ 
Accurate low blo d v lume analysis ☒ ☑ ☑ 
Ease f pr cess ☒ ☒  
Low cost  ☒  
Support for search/flex bility ☑ ☒ ☑ 
Cl nical r levance 
 
☒ 
 
☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = dis dvan ages; ☑ = dvantages. 
6 1. Flow Cytom try 
Flow cytometry can be us d for c ar c er zin  tumor cell dissemi tion pattern  an kineti s in 
preclinica  models of cancer met sta is [64]. Using flow c o etry i a recl ical setting, human 
cancer cells can b  effectively ide t f ed among mou e leuk cyte . This pr c ss has be n des r b  
previously by All n et al. (2005) [73]. B i fly, flow cyt m try an b used t  id ntify CTC  based on 
their size, positiv  stai ng wi h a FITC-conjug d nti-hu an l uko yt  a t en (HLA) a tib d , 
negative stai ing with a phyco rythrin (PE)-conjugated nti-mou  pa -leukocy e CD45 a tibody, 
and aneuploidy DNA content based propidi m i ide (PI) st i ing [64,73]. 
This CTC an ly is a pro ch w s one of th f st to allow for ar y d ec ion and qua tific tion 
of are etas at c tumor cells in the blood of mice and this led to evide ce of CTC contribution to the 
devel pment of meta atic disease [64]. Util zing precli ical po ntial f low cy ome ry analy is 
of CTCs, studi s have s essed tu ell d semi ation p tterns usi g spo taneous and 
experimental CTC/metasta is m del  [64] and rack th  kinetics of T  generation in iv  by 
analyzing multiple breast c ncer c ll lin s nd h i  r lation h p betw en CTCs and me a ta is ( e 
Figure 3a) [72].
Flow cytom ry is on  of  mos  ost-eff ctive CTC mer tion ech log es ava lable f r 
preclinical CTC analy is, which allows for arvesting of viable cells for downstream analy is if a 
fluorescence activated cell sorting (FACS) instrument is used. However, this particular method of 
CTC enumeration relies heavily on expression of HLA on the hu an tumor cells [73]. A  such, the 
use of cell lines with lower or absent levels of HLA expression may pr sent difficulties with this 
technique. This is particularly r levant when considering f ture a plication of this assay to 
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mice or NOD/SCID ice vi  the ma ary fat p d (MFP). At several time p int  post-inj ctio , mice 
wer sacrificed and blood (1 L)  tissue  w e coll cted a d analyz d. CTC ki etics in blood was 
easu ed by flow cyto tr  (left pa l; mean ± SEM, n = 5 mi /group) an  th  incidence of lung 
etastasis (% of mice in th  gr up) wa measur d as sessed sto thol gy (right panel). Adapted 
from R f e ce [72]. (b) Human pr stat  ca cer cell  of differing m tastatic ability w re inje ted into 
ale nude mice vi  the right d rsolat al lob  of the prostat  gla d. A  several timepoint  post 
inj ction, mice were s crificed and blo d (100 µL) was coll cted and plit int  two 50 µL aliquots 
b fore n lysis using n dapted CellSe rch® T  a say as ss TC k netic  between epithelial 
(LNC P, C4-2B) v rsus mesenchy al (PC-3M, P -3) cell li es (left pan l, mean ± SEM, n = 5–12 
ic /g oup). To compare the diff nce in CTC umb r tect d sing EMT-depende t ( pCAM+) 
v rsus EMT semi-independe t (EpCAM+/HLA+) ad pt d C llSe rch® says in matc ed ples 
(right an l; m an ± SEM); positive valu s = m e CTC  ected with EMT emi-i dependent assay, 
gative valu s = more CTCs d t cte  wi h EMT-d p de t ssay. * = sig ific nt difference relative 
to P -3; α = significant differenc  rel tive to LNCaP C4-2B; δ = significant difference rel tive to 
LNCaP (p ≤ 0.05). Ad pted fro  Refere ce [45]. (c) Human PC-3 prostat  c c r cell  (mese hymal 
phenotype) were inje t d into male u e mice vi  th  right do solateral lobe f the prostate gland. At 
sev ral im poi t , p st injec i n bl od (100 µL) was se ially c llected a analyz d using the 
Par r ix™ CTC n lysis platform. 
Table 2. Co p riso  f r clinic l TC analysis pproaches. 
Feature Flow Cytometry CellSearch® Parsortix™ 
Sensitivity ☑ ☑☑☑ ☑ ☑ 
Cap ur s cells i de endent of phenotyp  ☒ ☒ ☑ 
Ability f r downstream an lysis ☑ ☒ ☑  
Accurat  low bl od volume analysis  ☑ ☑ ☑ 
Ease of process   ☑ 
Low cost ☑ ☒ ☑☑ 
Support for research/flexibility ☑☑  ☑  
Clinical relevance 
 
 
 
☑ 
(FDA) 
 
(CE Mark) 
☒ = is t ; ☑ = advantages. 
6.1.1. Flow Cytometry 
Flow cyt met y c n be sed for cha a t rizing tum r ell dis m atio pa t r s nd ki etics in
pre li cal d l  of ncer m tastasis [64]. U i flow cyt et y i  a pr clini l setti g, human
canc r c lls c  b  ff v identifi d among m us  le k cytes. This process has been d cribed 
pr v ou ly b  Al n et l. (2005) [73]. Bri fl , low cyt m try can be use  to e tif  CTCs bas d 
th ir size, posi v  staini g w FITC-c njug t anti-hu leukocyte ige (HLA) antib dy,
g tive stai i g wi h a phyco ry rin (PE)- j g ted ti-m us  pan-leuk  CD45 tibod ,
and n u loidy DNA c n en  ba  pr pidiu io id  (PI) tain ng [6 ,73]. 
This CT  analysis appro ch wa  one f t  fi t t all w f  e rly etecti  nd qua t f cati
of ra e metas tic tum r el  i  the blo d of mi  n  thi  l d t  vid nc  of C  co tribu ion to th
d v l pment of m tastatic dis ase [64]. Utilizing th  preclinical p t ntial f fl w cytometry anal sis 
of CTCs, tudi s have assess d tu r c ll iss ina ion p terns usi g sp t ous and
experimental TC/metast sis mod l [64] d tr ked t e kin tics CTC g ratio  in vivo by
analyzi g multipl  b ast c r ll l nes a d h ir r latio hip b t  CTC  and m tas asis (see
Figur  3a) [72]. 
Flow cyt metry is one  th  mo  c t-e f ctiv  CTC u r tion t ch l gies available for
pr li cal CTC a aly i , ich llows fo ve ti g f viabl  c ll  f  dow s r m an y i  if a
fluor cence activated ll sorting (FACS) instrument is used. However, thi  particular method of 
CTC num ratio  r li  he vily o  xpr s ion f HLA n the hu an tumor cells [73]. As su h, the 
use f c ll lines with lower r absent lev l  f HLA xp sion may esent difficulties with this 
techniq e. This i  p rticularly relevant when consideri g future application of this assay t  
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ice or NOD/SCID mice via the ma ary fat ad (MFP). t sev ral ti e points post-injection, mice 
ere acrificed and blood (1 mL) an  tissues were ollected d analyze . CTC kinetics in blood was 
measured by flow cytometry (left anel; m an ± SEM,  = 5 mice/group) and the incidence of lung 
metastasi  (% of mice in th  group) was measured s s essed his opathology (right panel). Adapted 
f  R f r n  [72]. (b) Human pr stat ancer cells of iffering metastatic ability were injected into 
ale nu e mice via the right dorsolateral lobe of the rostate glan . At several timepoints post 
injection, ice were sacrific   blood (100 µL) as co lected and split into two 50 µL aliquots 
b for  analy is using n adapt  CellSearch® CTC assay to ass ss CTC kinetics between epithelial 
(LN aP, 4-2B) versus mesenchym l (PC-3M, PC-3) cell lines (left pa el, mean ± SEM, n = 5–12 
ice/group). o compare th  iffere ce in CT  u ber detected using EMT-dependent (EpCAM+) 
versus T se -ind pendent (EpCAM+/HLA+) adapted C llSearch® assays in matched samples 
(right panel; ean ± SEM); posit ve value  = ore CTCs e ected with EMT semi-in pendent assay, 
n gative valu s = mo  TCs detected with EMT-d pendent assay. * = significant ifference relative 
to P -3; α = significant difference relat ve o LNCaP C4-2B; δ = significant difference relative to 
LNCaP (p ≤ 0.05). Adapt  from Reference [45]. (c) Human PC-3 prostate cancer cells (mesenchymal 
phenotype) were i jected int  male nud  mice via the right dorsol teral lobe of the prostate gland. At 
several timepoints, post injecti n blood (100 µL) was er ally collected and analyzed using the 
Parsortix™ CTC analysis platfo m. 
T ble 2. Compariso  of reclinical CTC analysis approaches. 
F ature Flow Cytometry CellSearch® Parsortix™ 
Sen itivity  ☑ ☑ ☑☑☑ 
Cap ur s cells in ependent of phenotype ☒ ☒ ☑ 
Ability for down tream analysis  ☒ ☑☑  
Accura  low blood volume analysis ☒  ☑☑☑ 
Ease f pr e s ☒ ☒ ☑ 
L w cost  ☒  
Support for research/flexibility ☒ ☑☑☑ 
Clinical relevance 
 
☒ 
 
☑☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = d sadva tages; ☑ = dvantages. 
6.1.1. Flow Cyt ry
Flow cyt metry ca be used for cha act rizing umor c l d s e inatio pa ter s and ki etics in
pr cli cal del  of a r me tas s [64 U i g flow cytom try i a preclinical setting, human 
cancer c ll ca  be effect v y id ntified ng mou e uk cy es. This pro ess has been des ribed
previo sly by Al a   al. (2005) [73]. Briefly, flow tom try c n b  us d to iden ify CTCs ased on
their size, sitive t i i g w th FITC-conjugat d a i-hum  leuk cyte antige  (HLA) antibod ,
n gative st i ing wit   phy rythrin (PE)-co jugat d -mou e a -leukocyte CD45 antibod ,
and an u lo y DNA con en b s d pr pi ium odid  (PI) s ai i  [64,73]. 
This CTC analysi  appr ch w s on  f t e firs to al ow for e rly t ction and qu n ific ti n
f ra m tastatic tumor cells i  the blood of mi e and his led to evidence of  co tribution to the 
d v lopm nt of asta i d s as [64]. Uti izi g the pr cl i l potent al of fl w cyt metry nalysis
of TC , stud es h v  assessed um r c ll di i ti n pa t n  using pont eous and
ex erim ta CTC/ as a  models [64] an t ck d the kinetics f CT  generation in vivo by
analyzi g ultipl br ast c nc r cell lin s a d h ir relati p b t ee  CTC  and m tasta i  (se
Fig re 3a) [72]. 
Flo  cy om try s one of the st cos - f ectiv  CTC enum ation te h logies available for
precli ical CTC analysis, which allo s for harvesting of vi ble cells for downstream analysis if a 
fluorescence activat d cell sorti g (FACS) i strument is sed. However, this particular method of 
CTC enum ration relies h avily on expression of HLA on the uman t mor cells [73]. As such, the 
u e of cel  lines with lower or absent lev ls of HLA xpr sion may present difficulties with this 
technique. T is is particularly relevant when considering future application of this assay to 
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ice r NOD/SCID mice via the ma mary fat ad (MFP). t s v ral ti e p ints post-injection, mice 
re acrificed and blood (1 m ) an tissues w re ollecte an  analyz d. CTC ki etics in blood was 
asur d by flow cyto try (left an l; mean ± SEM, n = 5 mice/group  and th  incidence of lung 
metast i  (% of mice in t e group) was m asured s as essed histopath logy (right panel). A apted 
from R f n  [72]. (b) Human pros ate cancer ce ls of iffering metas atic ability w re injected into 
ale nude mice via the right orsolatera  lobe of the pros a e glan . At several timepoints post 
injection, mice r  sacrific   blood (100 µL) was co lecte and split into two 50 µL aliquots 
b for  analysis using an adapte  ellSear h® CTC assay to as ess CTC kinetics between epithelial 
(LN P, 4-2B) versus m senchy l (P -3M, PC-3) cell lines (left panel, ean ± SEM, n = 5–12 
m ce/group). To co pare th  diff rence in T  u ber tected using EMT-dependent (EpCAM+) 
versus EMT e i-ind pendent (Ep AM+/HLA+) adapted C llSearch® assays in matched samples 
(right panel; mean ± SEM); posit ve valu  = more CTCs d e ted with EMT s mi-in ependent assay, 
ga ive valu s = more CTCs d tected with EMT-d penden  assay. * = significant diff rence relative 
to P -3; α = signi icant diff rence relative to LNCaP C4-2B; δ = significant diff rence relative to 
LNCaP (p ≤ .05). Adapte  from R f re  [45]. (c) Human PC-3 r s ate cancer cells (m senchymal 
phenotype) w r  injec ed int male nude m ce via h  right orsolateral lobe of the pros ate gland. At 
several tim points, post injecti n blood (100 µL) a  erially collected and analyzed using the 
Parsor ix™ TC anal i  platform. 
ble 2. Co a iso  of recl nical CTC analy is approaches. 
Featur  Fl w Cytometry CellSearch® Parsortix™ 
S it vity  ☑ ☑ 
Captu s cells i ependent of phenotype  ☒ ☑ 
Abi ity for d wn trea  analy is  ☒ ☑ 
A curate low blo d v lume analysis  ☑ ☑ 
Ease f pr cess   ☑ 
Low cost  ☒  
Support for r search/flex bility  ☒ ☑ 
Cl nical r levance 
 
☒ 
 
☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = disadvant g s; ☑ = adva tage . 
6 1. Flow Cyt etry 
Flow t e ry ca b  used fo ch racter zing umor c l d s emi atio pa rns and ki etics in
precl cal del of a c r m t ta s [64]. Using flow cyto etry in a preclinical setting, human 
canc r cells c  b  effectively id ntified m ng mou  uk cy s. This pro e s has bee  des ribed
previ usly by All  al. (2005) [73]. Briefly, flow c m ry can b us t ide if  CTCs based 
th ir siz , sitive tai ing with FITC-c nju at d a i-hum n l uk cyte tigen (HLA) tibod ,
n gative t i g wit  hy o ry hrin ( E)-co ju a d -mou  -le kocyte CD45 antibo y,
d an u o dy DNA c t bas d propidium o i  (PI) stai g [64,73]. 
This CTC ana ys  a pro ch w s one f t firs  to all w for rly d ectio  and qu ification
of a etas atic tumor cells in the blood of mice a d his led to evidenc  of CTC contribution to the 
d v l p ent of ta a dis as [64]. Util zi g th precli i l pot nt al of fl w cyt metry naly is
of CTCs, stud s have as essed um r cell dis mi ti pa t rns u g pont eous and
experim t TC/m tas a  models [64] an  t ack d the kineti s of CT  generation in ivo by
ana yzi g ultipl br ast c cer c ll lin s a d thei  relati s p b tween CTC and metasta is (se
Figure 3a) [72]. 
Flow cy ometry is one f th  m st cost- f ectiv  CTC enum a ion te hn l gies av ilable for
preclinical CTC analy is, which allo s for harvesti g of viable cells fo  downstream analy is if a 
fluorescence activat d cell sorting (FACS) nstrument is used. However, this particular method of 
CTC enum ation r lies heavily on expression f HLA on the u an tumor cells [73]. A  such, the 
u  of cell lines with low r or absent lev ls of HLA ex ression may pr sent difficulties with this 
technique. T is is particularly r levant whe  considering f ure a plication of this assay to 
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ice or NOD/SCID mic  ia the a mary f t p  (MFP). At s veral time point  post-injection, mice 
w r  sa rifi  and b ood (1 m ) and tissues w re collecte n  analyzed. CTC k netics in blood was 
m asur  by flo  cyto etry (left el; mean ± SEM, n = 5 mice/group) and the incidence of lung 
etast is (% of mic  in t  group) was easured as esse  histopath logy (right panel). A apted 
from R f nce [72]. (b) Human pros ate can r cells of iffering metas tic ability w r  injected into 
male nude ice via the ri ht orsol teral obe of the pr a e gland. At several timepoints post 
injection, ic re sa rifice  and blood (100 µL) w s collecte  an  split into t o 50 µL aliquots 
b fore analysis using an adapted llSear h® TC ssay to ess CTC k netics b tween epithelial 
(LN aP, C4-2B) versus m senchymal (PC-3M, PC-3) cell lines (left panel, mean ± SEM, n = 5–12 
m ce/group). To compar the diff rence in CTC u b r tected using EMT-d p dent (EpCAM+) 
versus EMT semi-indep ent (EpCAM+/HLA+) adapte  C llSearch® ass y  in matched samples 
(right pan l; mea  ± SEM); p sitive valu s = mor  CTCs d tecte  with EMT semi-indep dent assay, 
nega ive values = more CTCs d tected with EMT-d p den  assay. * = significant diff rence relative 
to PC-3; α = significant diff re ce relative to LNCaP C4-2B; δ = significant diff rence relative to 
LNCaP (p ≤ .05). A apted f m R f re  [45]. (c) Human PC-3 pros ate can r cells (m senchymal 
phenotyp ) w  injected in o mal  nu  mice via he right orsol teral l be of t  pros ate gland. At 
several timepoints, post injection bloo  (100 µL) wa  serially collec ed and analyzed using the 
Parsortix™ CTC analy is platform. 
able 2. Com iso  of recl nical CTC analy is approaches. 
F ature Fl w Cytometry C llSearch® Parsortix™ 
Sensit vi y ☑ ☑ ☑ 
Captur s cells indep dent of phenotype ☒ ☒ ☑ 
Ability f r d wnstre  analy is ☑ ☒ ☑ 
Ac urate low blood volume analysis ☒ ☑ ☑ 
Ease of process ☒ ☒ ☑ 
Low cost ☑ ☒  
Supp t for search/flex bility ☑ ☒ ☑ 
Cl nical r levance 
 
☒ 
 
☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = is dva tages; ☑ = dvantages. 
6 1. Flow Cytometry 
Flow t me ry ca b  u ed fo ch ra ter zing umor c ll d ssemi atio  pat rns and ki etics in
pre l ical o el f a c r m tasta s [64]. Using flow cyto etry i a pre linical setting, human 
a r cells  b  ff ctively id n fi d m ng mo ukocyt s. This pr ess has bee  des ribed
p vi usl  by Allan et a . (2005) [73]. Bri fly, flow cytom try ca  b  us d t identify TCs based on
th ir s z , p sitiv s ai g wi  a FITC-co ju ate  i-h n l uk c te tigen (HLA) tibody,
n gative st  with a phy oery hr  (PE)-co juga d -m u  p -le koc te CD45 a tibo y,
and u idy DNA co te t bas d r pi ium od (PI) sta g [64,73].
This T  ana y s pr ach was one f t e firs  t  allow fo early d ecti and qu n if cation
of eta atic tumor cells in t  blo d of mi e a d th s led to vid nce of CTC contributi n to the 
d vel pme  of ta a  dis as [64]. Util zi g th p eclini l pot ti l of fl w cytometry naly is
of TCs, stu ie  have s s d tum r c ll dissem nat  p tterns u ng spo t eous and
xperim t l TC/meta t s odel [64] an  rack d the kineti s of T  gener tio  in ivo by
ana yzi g mu tip b a  r c ll lines a d thei  rela i ns ip b tween TC and metasta is (se
Figure 3a) [72]. 
Flow c tometry is e of h  m st ost- f ectiv  TC u a io e hn l gie av ilable for
preclinical TC a aly is, which allow  f r harvesting of viable cells for dow stream analy is if a 
fluores ce activa ed cell sorting (FACS) nstrument is use . However, this particular meth d of 
TC enumeration relies avily o expressi n of HL  on t e u an tumor cells [73]. A  suc , the 
u of cell lines with low r or absent lev ls o  HLA expressi  may pr sent difficulties with this 
technique. This is pa ticularly r levant whe  considering f ure a pl cati n of thi  assay to 
Clinical rel vance
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ice or NOD/SCID m ce via the ma ry f t pad (MFP). At several ime point  post-i jecti n, mice
were sa rificed and blood (1 mL) and tissu  were olle ted and analyzed. CTC kin tics i  bloo wa
easure  by flow cytometry (left panel; ean ± SEM, n = 5 mice/group) and th  incid nce of lu
metastasis (% of m ce in the group) w s easur  s as e s d histopath gy (right el). dap d
from Reference [72]. (b) Human pro tat  cancer ll of differing m tastatic ability wer  i jected into
male nude ice via the right dorsolateral lob  of the pro tate gland. At several time oints po t
injection, mice were s crific d and blood (100 µL) was oll a d sp it i o wo 50 µL aliquots
b fore analysis usi g an a a ed CellSearch® C C assay to assess CT  kinetics between e ith lial
LNCaP, C4-2B) versus mes nchy al (PC-3 , P -3) ce l lines (left an l, mean ± SEM,  = 5–12
mice/group). To comp re the ifferenc  in CTC n b r detected using E T-depend nt (EpCAM+)
versus EMT se i-independent (EpCAM+/HLA+) adapted C llSearch® ssays in matched s mples
(right panel; mean ± SEM); sitiv  values = more CTCs detect with EMT semi-independ t ssay,
negative valu s = more CTCs detected with EMT-d p nd nt a say. * = signifi ant diff r nce relativ
to PC-3; α = significa t diff rence r l tive to LNCaP C4-2B; δ = sig ificant differenc  r lative t
LNCaP (p ≤ 0.05). Adapted fro  Ref rence [45]. (c) Hum n PC-3 pr state cancer cells (mesenchymal
phenotype) were injected into male nude mice via the right do solateral l be of th  pr state gland. At 
several timepoints, pos  injection blo d (100 µL) was s riall  olle ted a d analyzed using the 
Parsortix™ CTC analysis platform. 
Table 2. Comparison of preclinical CTC analysis approaches. 
Feature Fl C t me y C lSearch® Parsortix™ 
S nsitivity ☑  
Captures cells independent of phenotype 
Ability for downstream ana ysis  
Accurate low blood volume analysis ☑ 
Ease of process  ☒  
Low cost ☑☑☑ ☒  
Support for research/flexib lity ☑☑ ☒ ☑☑☑ 
Cli ical rel vanc
 
☒ 
 
☑☑ 
(FDA) 
☑ 
(CE M rk) 
☒ = disad tages; ☑ = ad antages. 
6.1.1. Flow Cytometry 
Flow cytometry can be used for charact rizing tumor cell dissem nation patterns and kinetics i  
preclinical models of ca cer met stasis [64]. Using flow cytometry in a preclinical setting, human
cancer cells can be effectively identified am ng mous  leukocytes. This process has been describ d 
previously by Allan e  al. (2005) [73]. Briefly, fl w cy ometry an be s to ide tify CTCs base  on 
their size, positive stai ing with a FITC-conjugated anti-hu an leukocyte antige  (HLA) antibody, 
neg tive st ining with a phycoerythrin (PE)-conjugated anti- ouse pa -leukocyte CD45 antib dy, 
and aneuploidy DNA content based propidium iodide (PI) staining [64,73]. 
his CTC analysis approach was one of th  first to allow for early detect on and quantificati n 
of rare metastatic tu or cell  in the blood of mice nd this le  to vidence of CTC con ribution t  the 
development of metast tic disease [64]. Utilizing the preclin cal pot ntial of flow cyto e ry nalysis 
of CTCs, studies have assesse  tu or cell dissemination patter s using spont neous and 
experimental CTC/metastasis models [64] and track d the kinetics of CT  generation in vivo by 
analyzing multiple breast cancer cell lines and their rela ion hip b t en TCs and etas asis (s e 
Figure 3a) [72]. 
Flow cytometry is one of the most cost-effective CTC enumeration technologies available f r 
preclinical CTC analysis, which allows for harvesting of viable cells for downstream a alysis if a 
fluorescence activated cel  sorting (FACS) inst ume t is used. Howev r, thi  particular meth o  
CTC enumeration relies heavily on exp ssion of  on the hu a  tumor cells [73]. As such, he 
use of cell lines with lower or absent levels of HLA expression may present difficulties with this 
technique. This is particularly relevant when considering future application of this assay to 
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mi   NOD/SCID mi e via th  m mmary at pa (MFP). At s veral time p ints p st-injec io , mice 
r  s crificed and lo d (1 mL) and tissu s w r  col cted and nalyzed. TC kinetic i  blood was 
easured by flo  cyto etry (l ft pane ; an ± SEM, n = 5 mic /group d the incidence of lu g 
metastasis (% f ice n the group) was m asured as assess  histopathology (right anel). Adapt d 
from R fer ce [72]. (b) Hu a  prostate ca cer cells of differing e ast tic bi ity we e injected into 
male nude ice vi  the right dorso t ral l b f the prostate gland. A v ral t m oints po t 
i j ction, mic w r sac fice  and bl od (100 µL) was coll cte  and s lit to two 50 µL aliquo s 
before analy is us ng  a apted C lS rch® CT  ass y to assess T k etics betw en p thelial
( , C4-2B) v sus mesen hy al (PC-3M, PC-3) c ll li es (left p nel, m an ± SEM, = 5–12 
mic /gr up . To compare he diff e c  in TC number detect d using EMT-d p ndent (EpCAM+)
versu  EMT s mi-inde e de t (EpCA +/HLA+  ad pte CellSear h® assays  match d s pl s 
(right panel; me  ± SEM); posi ive v lues = m e CTCs detected with EMT semi-independent assay, 
negative values = more TCs detected with EMT-dependent assay. * = significant difference relative 
to PC-3; α = significant diff re ce rel tiv  to LNC P 4-2B; δ = significant difference rel tive to 
LNCaP (p ≤ 0.05). A apted from Reference [45]. (c) Human PC-3 prostate cancer cells (mesenchymal 
phenotype) were injected into male nude mice via the right orsolateral lobe of the prostate gland. At 
several imepoints, post injection blood (100 µL) was serially collected and anal zed using t e 
Parsortix™ CTC analysis latform. 
Ta  2. C mparis n of r clinic  CTC analysis approaches. 
Feature Flow Cytometry CellSearch® Parsortix™ 
S sitivi y ☑  ☑☑☑ 
Captu s cells independent of phenotyp  ☒  ☑ 
Ability for down t eam analysis   ☑  
Accurate low bl od volume analysis  ☑ ☑  
Ease of pro ess  ☒ ☑ 
Low cost   ☑  
Support for research/flexibility  ☒ ☑  
Clinical relevance 
 
☒ 
 
☑☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = dis dvantages; ☑ = dv n ages. 
6.1.1. Flow C tom try 
Flow cyto etry can be used for c aracterizi g tumor cell dissemi tion patterns and kineti s i  
preclinical mo els of cancer metastasis [64]. Using flow cyt etry in a precli ical setting, human 
cancer cells can be effectively i entified am ng mou e leukocytes. This pr cess has been described 
previously by Allan et al. (2005) [73]. B iefly, flo cyt metry ca be used t  identify CTCs based o  
th ir size, positiv  st ining with a FITC-conjug t d a ti-human leukocyte a tigen (HLA) antibod , 
negative taining wit  a phyc erythrin (PE)- onjugat d a ti- ouse a -le koc te CD45 antib d , 
and aneuploidy DNA content base  propidium i ide (PI) staining [64,73]. 
Th s CTC analysis pproa h was o  of the first to ll w for early detection quantification 
of rare metastatic tumor cells in the lood f mice and this le  to evi ence f CTC contribution to the 
development of etastatic diseas  [64]. Utilizing the preclinical po ntial of flow cyto etry ana ysis 
of CTCs, studies have assessed tum r cell disseminatio  patterns usi g spontaneous and 
expe imental CTC/m tastasis models [64] a d tracked the ki etics of CTC gene ation in viv  by 
analyzi g ultiple brea t cancer cell lines an  their relationship between CTCs and meta tasis ( ee 
Figure 3a) [72]. 
Fl  cytom try s one of the m st ost-effective CTC enumeration tech ologies ava l ble for 
preclinical CTC analysis, whic  allows for harvesting of viable cells for downstream analysis if a 
fluorescence activated cell sorting (FACS) instrument is used. However, this particular method of 
CTC enumeration relies heavily on expression of HLA on the human tumor cells [73]. As such, the 
use of cell lines with lower or absent levels of HLA expression may present difficulties with this 
technique. This is particularly relevant when considering future application of this assay to 
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mi  r NOD/SCID mi e via the m mary at pa ( FP). At s veral time point  p st-injec o , mice 
wer s crificed and blood (1 mL) and tissue  wer  col ct d and an lyzed. CTC kinetics i  blood was 
me sured by flo  cyto etry (left panel; ean ± SEM, n = 5 mic /group) and the incid ce of lu g 
etasta is (% f ice in the group) was asur d as as ess d histopath logy (right panel). dapt d 
from R f rence [72]. (b) Hu a  pros ate ca c r cells of differing et s tic abi ity w e injecte into 
male ude ice via the right dor o ral l b of th pros ate gla . A  s veral t m points post 
i j ction, mic w sacrific  an bl o  (100 µL) was collecte  and spl t o t o 50 µL liquo s 
before analy is us g a apt d C lS arch® CT  ass y as ess TC k tics betw n ep thelial 
( , C4-2B) v rsus m senchy l ( M, PC-3) ll lin s (lef  p el, an ± S , = 5–12 
mic /group . To compare th d ff re c  in CTC number d tect d us ng EMT-d p ndent (EpC M+) 
ver us EMT semi-indepe dent (E CA +/HLA+  d pte CellSearch® ssays i  matched s pl s 
(right nel; e  ± SEM); positive v lues = m e CTCs d tecte  with EMT semi-independent assay, 
negative values = more CTCs d tected with EMT-dependent assay. * = significant diff rence relative 
to PC-3; α = significant diff rence rel tiv  to LNC P 4-2B; δ = significant diff rence rel tive to 
LNCaP (p ≤ .05). A apted from R f rence [45]. (c) Hu an PC-3 pros ate cancer cells (m senchymal 
phenotype) w re injected into male nude mice via the right orsolateral lobe of the pros ate gland. At 
several timepoints, post injecti n blo d (100 µL) wa  serially collected and analyzed using the 
Parsor x™ CTC analy is platform. 
T ble 2. Co paris  of precl ica  CTC analy is approaches. 
Featur  Flow Cytometry CellSearch® Parsortix™ 
Sensit vity ☑ ☑ ☑ 
Capt res cells independent of phe otyp  ☒  ☑ 
Ability for do nstream analy is ☑   
Ac urate low blood volume analysis ☒ ☑ ☑ 
Ease of process  ☒ ☑ 
Low cost ☑   
Support for r search/flex bility ☑ ☒  
Cl nical r levance 
 
☒ 
 
☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = dis dvantag s; ☑ = dvanta es. 
6 1. Flow Cytometry 
Flow cytometry can be used for ch racter zin  tumor cell dissemi ation patterns and kinetics in 
preclinica  models of cancer etasta is [64]. Using flow cyt metry in a precl ical setting, human 
cancer cells can b  effectively identified a o g mouse leukocyte . This process has be n describe  
previously by All n et al. (2005) [73]. Briefly, flo  cytometry an be used t id ntify CTCs based o  
their size, positiv  stai ng with a FITC-co juga ed anti-human l ukocyte antigen (HLA) antibody, 
negative stai ing with a phyc rythrin (PE)-conjugated nti- ou  a -leuk cyte CD45 antibod , 
and aneuploidy DNA content based propidiu  io ide (PI) stai ing [64,73]. 
This CTC analy is a proach was one of the f st to allow for ar y d tection and quantific tion 
of are metas at c tumor cells in the lood of mice and this le  to evidence f CTC contribution to the 
development of meta atic disease [64]. Util zing the preclinical pot ntial of flow cy o e ry analy s 
of CTCs, studi s have as essed tum ell d ssemination patterns usi g spontaneous and 
experi ental CTC/metasta is models [64] and tracked the kinetics of CTC generation in ivo by 
analyzing multiple breast c ncer cell lin s and thei  relationship between CTCs and meta ta is (s e 
Figure 3a) [72].
Flo  cytometry is o e of th  m st cost-eff cti e CTC meration tec logies available f r 
preclinical CTC analy is, which allows for harvesti g of viable cells for downstream analy is if a 
fluorescence activated cell sorting (FACS) instrument is used. However, this particular method of 
CTC enumeration relies heavily on expression of HLA on the human tumor cells [73]. A  such, the 
use of cell lines with lo er or absent levels of HLA expression may pr sent difficulties with this 
technique. This is particularly r levant when considering f ture a plication of this assay to 
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ce or NOD/SCID ice v a the mammary fa  pa (MFP). At v r l t m oints p st-injection, mice
wer  s crific bloo  (1 mL) nd tissue were collected and a alyz d. CTC kinetics in blood w s
ea ur d b f ow yto etry (left n ; ea   5 mic /grou ) and th  i cidence of lung
t stasis (% i group) w measure s assesse  h s opa hology (right pa l). Adapted
from R ferenc  [72]. (b) uman ro tat  cancer c lls of iffer g m tas ati  b ity were inj cted into
male nud  m c ia th  righ  dorsolateral lob of t e pro t t g an . At everal timepoi ts po t
injec on, mic w r  sacrificed an blood (100 µL) wa  co lected nd pl t nto wo 50 µL aliquo s
b fore an lysis usi g an adapted C llSe rch® CT ssay o a sess CTC kinet cs betw n pith lial
(LN aP, 4-2B) versus m senchymal (P -3M, PC-3) l ines (left pa l, ean ± SEM,  = 5–12
mice/grou ). To compar  th  diff nc in CTC n mbe  etected usi g MT- e endent (EpCAM+)
us EMT se -in epend n (EpCAM+/HLA+) adapt  Ce lSe r ® as ys in m tch amples
( ight anel; ean ± SEM); ositive values = more CTCs etected with EMT semi-independent assay, 
negative valu s = more CTCs det ct d with EMT-dependent assay. * = significan  difference relative 
to PC-3; α = signific t difference rel tiv  to LNC P 4-2B; δ = signifi nt difference relative to 
LNCaP (p ≤ 0.05). Adapte fro  Reference [45]. (c) Hum  PC-3 pro tate ca er cel s (mesenchymal 
pheno ype) wer  i jected into m l  nu e mice via the right d rsolateral lobe of the prostate gland. At 
everal imep nts, post injection b ood (100 µL) as serially coll cted and analyzed using the 
P rsortix™ TC anal si  platform. 
Table 2. Co p ri o  of reclinic l CTC analysis approaches. 
Feature Flow Cytometry CellSearch® Parsortix™ 
Se itivity  ☑  
Ca tures cells i depe dent of phenotype ☒  ☑ 
bility f r downstream l i  ☑ ☒  
A curate low blood volume analysis    
Ease of process ☒  ☑ 
Low ost ☑☑   
Support for research/flexibility ☑☑ ☒  
Clinical relevance 
 
☒ 
 
☑ 
(FDA) 
☑ 
(CE Mark) 
☒ = disadvant g s; ☑ = adva tages. 
6.1.1. Flo  Cyto etry 
Flow cyt m try ca be used for chara terizing tumor c ll diss min tio  pat er s and ki etics in
precli i l odel  of a c r etastasis [64]. Using flow cyto etry i  a preclinical setting, human 
cancer ells can be effectively id ntifi d m ng mouse leukocytes. This pro s has been des ribed
previously by Allan et al. (2005) [73]. Bri fl , flow cytom ry ca  be use to id tify CTCs based 
t eir size, posit ve staining wit  FITC-conjug t  a i-hu n leuk cyte antigen (HLA) antibody,
egat ve st i ing wit  a phy erythrin (PE)-co juga d a -m use pan-leukoc te CD45 a tibod ,
and aneuploidy DNA co tent based pr pidium odid  (PI) stai i g [64,73]. 
This CT  naly is appr ac  wa  ne f t e fi s  to allow f r e rly detectio  a d qu ificati n
of ra m ta tatic umor cells i  th  blood of mic  and this led to evidence of C  co tribution to the 
d v lopment f m tasta i  diseas [64]. Uti z g the preclini al potential of flow c to etry nalysis
of CTCs, tudi s have ass sse  tu r cell disseminati n patter s usi g spont eous and
experim t l TC/metasta s models [64] an  track d the kinetics of CTC generatio  in vivo by
analyzi g multiple br ast c ncer cell lines a d their relations ip bet e n CTCs and metastasis (se
Figure 3a) [72]. 
Flow cyt metry i  one f the most cost- f ectiv  CTC nu e ation te h logies available for
prec i cal CTC n lysis, w ich allows f r harv sti g of viable c lls for dow stream analysis if a 
fluores nce activated cell sorting (FACS) instrument is used. However, this particular method of 
CTC numer tion r lies h avily n expression of L  on the hu an tumor ells [73]. As such, the 
use of cell lines with low r or absent l vel  of HLA ex e sion may pr sent difficulties with this 
technique. This is particularly relevant when considering future applic tion f this assay to 
(CE Mark)
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mice or NOD/SCID mice via the mammary fat p d (MFP). At s ve  i e point  post-inj ti , mi
were sacrificed and blood (1 mL) and tissue  w  collect d nd analyz d. CTC kin ics in bl od w s
measured by flow cyt m try (l ft panel; n ± SEM, n = 5 ice/gr ) and th cid ce of lung 
metastasis (% of mice in the group) was m a ure  a  assessed hist pathology (rig t pa l . Ad pted 
from Reference [72]. (b) Hum  prost te cancer c ll  of d ffe ing metast tic bi ity were nj ct  into 
male nude mice via th  right dorsolat ral l b of th p ost te g n . A  s ver l timepoint  p st 
injection, mice were sacrificed and blo d (100 µL) was c l ected nd pl t in o w 50 µ  iquots 
before analysis using an adapted CellSearch® CTC assay to sess CTC kin ti between epithe i l 
(LNCaP, C4-2B) versus mesenchymal (PC-3M, PC-3) c ll l s (l f  p n l, m a ± SEM, n = 5–12 
mice/group). To compare the diff rence in CTC u ber d c d usi g MT- t )
versus EMT semi-independent (EpCAM+/HLA+) adapt  Ce lSe rch® ssa  in m ched samples 
(right panel; mean ± SEM); positive values = mor  CTCs d t cted with EMT semi-indepen nt ssay, 
negative values = more TCs detected with EMT-dependent ss y. * =  rel tive 
to PC-3; α = significant difference relative to LNCaP C4-2B; δ = significant iffere ce relative t
LNCaP (p ≤ 0.05). Adapted fro  R ference [45]. (c Huma  PC-3 rostate c ncer cells (mesenchymal 
phenotype) were injected into male nude mic  vi  the r ght do lateral lobe of th  prostate gland. At 
several timepoints, post injection blo d (100 µL) w s ser ly coll cted and ana yzed using the 
Parsortix™ CTC analysis platform. 
Table 2. Comparison of preclinical CTC nalysi  appr aches. 
Feature Flow Cyt metry CellSearch® Parsortix™ 
Sensitivity ☑ ☑☑ ☑☑☑ 
Captures cells independent of h n type ☒ ☒ ☑ 
Ability for downstream analysis ☑ ☒ ☑☑☑ 
Accurate low blood vol me analysis ☒ ☑ ☑☑☑ 
Ease of process ☒ ☒ ☑ 
Low cost ☑☑☑ ☒ ☑☑ 
Support for research/flexibility ☑☑ ☒ ☑☑☑ 
Clinical relevance 
 
☒ 
 
 
(FDA) 
☑ 
(CE Mark) 
☒ = disadvantages; ☑ = dv ntages. 
6.1.1. Flow Cytometry 
Flow cytometry can be used for char cterizing tumor cell disse ination atterns a d ki etics in 
preclinical models of cancer metastasis [64]. U ing flow cyt m try in a precli ical setting, h an
cancer cells can be effectively identifi d among mous  l ukocytes. T is pr s has been de cribed
previously by Allan et al. (2005) [73]. B iefly, flow cyt metry can b se  o de tify CTCs based on
their size, positive staining with a FITC-conjuga e  ant -hu a  leukocyte ntigen (HLA) antibody, 
negative staining with a phycoerythri  (PE)-c njugated anti-mo se pan-leukocyte CD45 an ibody, 
and aneuploidy DNA content based propidium iod de (PI) t i i g [64,73].
This CTC analysis approach was on of the first to all w for early dete tio and quan if cation 
of rare metastatic tumor cells in the blood of mi e and thi  led to evid nce f CTC co tribution to the 
development of metastatic disease [64]. Utilizing he preclinic l p tential of fl w cyto etry analysis 
of CTCs, studies have assessed tumo  c ll disse i i n patter  u ing p nta e us and 
experimental CTC/metastasis models [64] a d track d th  ki etics f CTC ge era ion in viv  by
analyzing multiple breast cancer cell lines and their r lationship bet e  CTCs and etastasis (see 
Figure 3a) [72]. 
Flow cytometry is one of the most cost-effective CTC enumerati  tech ologi  a ailable for
preclinical CTC analysis, which allows for harv s ng of viable cells for downstrea  analy is if a
fluorescence activated cell sorting (FA S) i strume t is u ed. Ho ever, thi  particular method of 
CTC enumeration relies heavily on expression of HLA n the hum n tum r cel [73]. s such, the 
use of cell lines with lower or absent levels of HLA exp ession may pr se  difficulties with this
technique. This is particularly relevant when considering future application of this assay to 
= disadvantages;
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metastasis (% of ice in the group) was e sur  as assess  i to athol gy (righ p n l). A a ed 
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LNCaP (p ≤ 0.05). Adapt d from R fere ce [45]. (c) Human PC-3 prostate c cer c l s (mes nchymal 
pheno ype) were injected i to male nude mice via th  right dors l teral lobe of the prostate gland. At 
several timepoin s, post i jecti n bl od (100 µL) wa serially coll c ed a d analyz d using the
Parsortix™ CTC analysis platf rm. 
Table 2. Comparis n of p clini al CTC anal sis approaches. 
Feature Fl w C t m tr  C llSe rch® Parsortix™
Sensitivity ☑ ☑☑☑ ☑☑
Captures cells independent f henotype ☒ ☒ ☑ 
Ability f r d wn t m analys s ☑ ☒ ☑  
Accurate low blo d volume alysis ☒ ☑ ☑☑
Ease of proc ss ☒ ☒ ☑ 
Low cost ☑☑☑ ☒ ☑☑ 
Suppor  for research/flexibility ☑☑  ☑☑☑ 
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☑
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6.1.1. Flow Cytometry
Flow cytometry  be us d for charact rizing tumor ll dissemination patter s an  kine i   
preclinical models of cancer met s a is [64]. Using low cytometry in  pr clini l set ing, huma  
canc r cells can be eff ctively ide tifi d mong ou e leukocyte . Th s pr ess h s bee  described 
previously by Allan t l. (2005) [73]. Briefly, flow y o e ry can b  u d to ide tify CTCs based n 
their size, positive stai i g with a FITC-conjugate  anti- um n leukocyt  antige  (HLA) ant body, 
negative stai ing with a phycoery hrin (PE)-conjugated n i-m u  pan- euk cyt  CD45 antibody,
and aneuploidy DNA cont nt based prop diu  iodid (PI) i ing [64,73]. 
This CTC analysis ap roa h was on of th  first to allow for arly d t tio  and qu tificatio  
of rare metastatic tumor cell  i  the blood f mice and his l d t  evidence f CTC co tr butio  to th  
development of met static disease [64]. Ut lizi g the prec inic l po enti  of low cyto etry an ly is
of CTC , tudies h ve asse sed t mor ll di s min tion patt r s us g ont ous an
expe iment l CTC/metastasis models [64] nd track d the kinetics of CTC g neration in vivo by 
analyzing mult ple breast can er cell lines and th ir rela ionship b twee  an  t sta i  (see 
Figure 3a) [72]. 
Flow cytometry is ne of the most cost-effe tive CT  enumer tio  technologies availabl  for 
preclinical CTC analysis, which allows for ar esti g of viable cells for downstrea  analysis if a 
fluorescence activat d cell s rti g (F CS) instr e t is used. However, this particular method f 
CTC enumeration reli s h avily on xpression of HLA on the huma  tumor cells [73]. As such, the 
use of cell lines with lower or abse t levels of HLA ex ression may present difficulties with this 
technique. This is particularly relevant when considering future application of this assay to 
= advantag .
6.1.1. Flow Cytometry
Flow cytometry can be used for characterizing tumor cell dissemination patterns and kinetics
in preclini al models of ancer metastasis [64]. Using flow cytometry in a preclinical setting, human
ca cer cells can be effectively identifie among mouse le kocytes. This process has been d scribed
previously by Allan et al. (2005) [73]. Briefly, flow tom try c be u e o id tify CTCs b d o
their size, positive stai ing with a ITC-co jugated ti-hu n leuk cyte anti e (HLA) ant o y,
n gative stai ing wi h a phy o rythrin (PE)-co jug t d anti-mouse pan-leukoc t CD45 nti y,
and an u loidy DNA conten b sed propidium iodid PI) staining [64,73].
This CTC analysis a roac wa on of th fir to all for rly det ction and qu tific tion f
rare metastatic tumor cells th blood f m ce an t is l d t evide ce of CTC contributio t the
development of met st tic disease [64]. Ut lizi g the pre linic l potential f fl w cytometry an lysis of
CTCs, studies have asse sed tum r cell dis emi t n att rns us ng p ntan ous exp rim nt l
CTC/ etastasis mod ls [64] an t cked th kin ics f CTC ge r ti n in vivo by analyzing multi le
breast cancer cell lines and their r lationship b twe n CTC a metastas s (se Figure 3 ) [72].
Flow cytometry is one of the ost c t- ff cti CTC um ra ion t ch olog s va lable fo
precli ical CTC analysis, which ows for harv sting of viabl c lls for ownstr am n ly s f
fluorescence activated cell sorti g (FACS) instr m nt i used. However, this par icula m thod f CTC
enumeration relies heavily n expres ion of HLA on the human tu or cells [73]. As uch, the use of
c ll lines with lower or absent l vels of HLA expr s i may pres nt diffi ulti wi h this tec qu .
This is particularly relev nt wh n c sidering futur appli atio of thi ass y t pr clinical m d ls
that make use of pr mary patient-d riv tumor c lls or CTCs. These TCs a likely to b ch
more heterogeneous than imm rtaliz d cell lines n t only i terms of xpr ss n of HLA r other
c ll surface markers but also in t rms of t roge eous size and nhanced fragility [74]. It is also
important to not t at th lower d tection limit for sensitivity fo this flow cytometry assay is 1 human
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CTC in approximately 10,000 mouse leukocytes [73]. The addition of a negative immuno-magnetic
depletion step targeting CD45+ cells before flow cytometry analysis increases the lower detection
limit to 1 CTC in 100,000 mouse leukocytes [73], which is improved but still 10-fold lower than the
clinical conditions of 1 CTC per 106 leukocytes [73]. The largest disadvantage of using this particular
HLA-based flow cytometry CTC enumeration assay is the inability to translate into a clinical setting,
since this technique exploits the differences in properties between mouse cells and human cells to
enumerate CTCs, which would not be present in patients.
6.1.2. CellSearch®
The CellSearch® system is the only FDA-approved technology for enumeration of CTCs in
metastatic breast, prostate, and colorectal cancer patients. Therefore, it is considered the clinical
“gold-standard” in CTC enumeration technology [74]. It provides a standardized method for highly
sensitive detection and quantification of CTCs from human blood samples. The CellSearch® first
automates blood sample preparation using the CellTracks AutoPrep® system and then scans the
samples using the CellTracks Analzyer II®. CTCs are enriched using immunomagnetic antibodies
for EpCAM, which is an epithelial cell adhesion molecule present on CTCs but not on leukocytes.
To identify CTCs, cells are stained for cytokeratins (CK) 8, 18, and 19 (epithelial filament proteins
also expressed by CTCs but not leukocytes), anti-CD45, a leukocyte marker, and DAPI to identify the
nucleated cells. After automated scanning of the blood sample, all potential CTCs are presented to
the user who must select, via semi-quantitative analysis, which events are true CTCs. The system
allows for (but does not necessitate) an additional user-defined marker of interest using a fluorescein
isothiocyanate (FITC) fluorescence channel to allow for single cell characterization of CTCs [74].
In order to use CellSearch® for preclinical analysis of CTCs in blood from mouse models, it is
necessary to adapt the human CTC assay for use with small blood volumes (ranging from 50 µL for
serial blood draws to 1 mL for terminal blood draws) [45,74] (see Figure 4). This adapted assay can
capture CTCs based on the exact criteria of the human test (EpCAM+/CK+/CD45−) (see Figure 4a) or
by including HLA as a positive selection marker to capitalize on the human-in-mouse model and to
broaden CTC capture criteria to include non-epithelial CTCs (see Figure 4b). Multiple components
of the CellSearch® kit can be used to achieve this in combination with manual immunomagnetic
separation of the sample. The enriched sample is then transferred to a MagNest™ for analysis using
the CellTracks Analyzer II® [45,74].
Preclinical studies using the adapted CellSearch® assay have illustrated the important impact
of the epithelial-to-mesenchymal transition (EMT) as it relates to CTC generation, CTC detection,
and metastatic progression. Lowes et al. (2016) [45] observed that mesenchymal prostate cancer tumors
shed greater numbers of CTCs more quickly and had greater metastatic capacity compared to tumors
with an epithelial phenotype. In addition, the traditional EpCAM-based CellSearch® assay missed
significantly more mesenchymal prostate cancer CTCs when compared to the adapted HLA-based CTC
enumeration assay [45,74]. Notably, although the EpCAM-based CellSearch® assay was able to capture
the majority of CTCs shed in early-stage disease with development of mesenchymal characteristics in
later-stage disease, the CellSearch® assay became more inefficient at enumerating the most aggressive
mesenchymal CTCs (see Figure 3b) [45].
The highly standardized nature of CellSearch® provides the advantages of reliability, consistency,
and high sensitivity when used in the setting of preclinical CTC analysis. Furthermore, because the
CellSearch® is approved for use in the clinical setting, preclinical CTC studies using the CellSearch® can
be readily translated to the clinic. However, the CellSearch® only provides one additional fluorescence
channel for added characterization of CTCs and is, therefore, limited with regards to user customization
and downstream molecular characterization [74]. CellSearch® is also very expensive both in terms of
initial infrastructure investment as well as assay reagents, which creates a barrier for researchers with
limited funds. However, the largest obstacle when using the CellSearch® is the dependency on the
epithelial marker EpCAM to enumerate the CTCs from blood samples.
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Figure 4. Overview of workflow for preclinical CTC assays using CellSearch®. (a) For the 
EMT-dependent CTC assay, 50 µL of whole mouse blood is incubated with components of the 
CellSearch® CTC kit (anti-EpCAM ferrofluid, Capture Enhancement Reagent, Nucleic Acid Dye, 
Staining Reagent, Permeabilization Reagent) as well as anti-mouse CD45-APC and anti-human 
HLA-AlexaFluor488. Samples are manually immuno-magnetically separated and transferred to a 
MagNest™ for analysis using the CellSearch®. EpCAM+/CK+/DAPI+/CD45−/HLA+ cells with a 
round/oval morphology were classified as CTCs. (b) For the EMT semi-independent CTC assay, 50 
µL of blood is lysed with NH4Cl. Samples are washed and labeled with anti-human HLA-PE, 
anti-human EpCAM-PE, and anti-mouse CD45-APC. Samples are washed and manually 
immunomagnetically enriched using the EasySep APC Positive Selection kit (StemCell Technologies, 
Vancouver, BC, Canada), incubated with CellSearch® Permeabilization Reagent and Nucleic Acid 
Dye and transferred to a MagNest™ for analysis using the CellSearch®. 
EpCAM/HLA+/DAPI+/CD45− cells with a round/oval morphology were classified as CTCs. 
Preclinical studies using the adapted CellSearch® assay have illustrated the important impact of 
the epithelial-to-mesenchymal transition (EMT) as it relates to CTC generation, CTC detection, and 
metastatic progression. Lowes et al. (2016) [45] observed that mesenchymal prostate cancer tumors 
shed greater numbers of CTCs more quickly and had greater metastatic capacity compared to 
tumors with an epithelial phenotype. In addition, the traditional EpCAM-based CellSearch® assay 
missed significantly more mesenchymal prostate cancer CTCs when compared to the adapted 
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was able to capture the majority of CTCs shed in early-stage disease with development of 
mesenchymal characteristics in later-stage disease, the CellSearch® assay became more inefficient at 
enumerating the most aggressive mesenchymal CTCs (see Figure 3b) [45]. 
The highly standardized nature of CellSearch® provides the advantages of reliability, 
consistency, and high sensitivity when used in the setting of preclinical CTC analysis. Furthermore, 
because the CellSearch® is approved for use in the clinical setting, preclinical CTC studies using the 
CellSearch® can be readily translated to the clinic. However, the CellSearch® only provides one 
additional fluorescence channel for added characterization of CTCs and is, therefore, limited with 
regards to user customization and downstream molecular characterization [74]. CellSearch® is also 
very expensive both in terms of initial infrastructure investment as well as assay reagents, which 
Figure 4. Overview of workflow for preclinical CTC assays using CellSearch®. (a) For the
EMT-dependent CTC assay, 50 µL of whole mouse blood is incubated with components of the
CellSearch® CTC kit (anti-EpCAM ferrofluid, Capture Enhancement Reagent, Nucleic Acid Dye,
Staining Reagent, Permeabilization Reagent) as well as anti-mouse CD45-APC and anti-human
HLA-AlexaFluor488. Samples are manually immuno-magnetically separated and transferred to a
MagNest™ for analysis using the CellSearch®. EpCAM+/CK+/DAPI+/CD45−/HLA+ cells with a
round/oval morphology were classified as CTCs. (b) For the EMT semi-independent CTC assay, 50 µL
of blood is lysed with NH4Cl. Samples are washed and labeled with anti-human HLA-PE, anti-human
EpCAM-PE, and anti-mouse CD45-APC. Samples are washed and manually immunomagnetically
enriched using the EasySep APC Positive Selection kit (StemCell Technologies, Vancouver, BC,
Canada), incubated with CellSearch® Permeabilization Reagent and Nucleic Acid Dye and transferred
to a MagNest™ for analysis using the CellSearch®. EpCAM/HLA+/DAPI+/CD45− cells with a
round/oval morphology were classified as CTCs.
6.1.3. Parsortix™
The Parsortix™ system uses a combination of microfluidic and size/deformability-based
approaches to separate CTCs from blood samples [75]. The cassettes use a step-wise system,
which gradually narrows to either 6.5, 8, or 10 µm depending on which cassette the researcher
chooses. Since CTCs are generally larger than blood cells, the stepwise microfluidic system allows
for the flow of blood cells through the cassette while the CTCs are captured. Different cassette sizes
allow the researcher to select a balance between high specificity/purity or high sensitivity of captured
cells [76]. Once the CTCs are enumerated from the blood, the Parsortix™ system allows the user a
variety of downstream options. These include harvesting the collected CTCs, using back-flow to gather
the cells for further molecular or functional analysis, or staining the CTCs directly within the cassette
(workflow described on the Parsortix™ website [77]). Studies have shown in cell spiking experi ents
that subsequent harvest of captured CTCs ranges from 54% to 69% of total captured CTCs with 99%
viability of harvested cells [76]. To enumerate captured CTCs, researchers can choose to fix the cells
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with or without permeabilization of the cell membrane and can stain with custom-selected fluorescent
antibodies to allow for visualization of the cells and quantitative analysis.
Analysis of CTC generation and dissemination in animal models of prostate cancer demonstrates
the value of using Parsortix™ for CTC analysis in the preclinical setting. In particular, Parsortix™
is able to detect and track the kinetics of highly mesenchymal CTCs generated following orthotopic
injection of the aggressive PC-3 human prostate cancer cell line (see Figure 3c). In addition, Parsortix™
allows for the analysis of both single CTCs and CTC clusters, the latter of which are difficult to assess
using flow cytometry or CellSearch® but have been shown to be biologically important for disease
progression [78]. This suggests that the size/deformability-based, epithelial-independent Parsortix™
may be a better tool for analysis of CTCs throughout EMT and disease progression to metastasis.
Parsortix™ is less expensive compared to the CellSearch® and allows for full customization of
subsequent staining of captured CTCs. It also allows the user to harvest captured CTCs for downstream
functional and molecular analysis, which is advantageous for preclinical biomarker development
and metastasis studies. Compounded by the ability to analyze <100 µL of blood compared to the
necessary 7.5 mL of blood using the CellSearch®, Parsortix™ is much more suited for preclinical
analysis of CTCs in mice [76]. Parsortix™ is approved for use in the clinical setting in Europe through
the CE Mark system, which suggests that preclinical CTC studies using Parsortix™ could be readily
translated to the clinic. However, the main advantage of using Parsortix™ over CellSearch® is the
ability to enumerate CTCs independent of their epithelial or mesenchymal status [76,79]. This allows
for preclinical studies comparing the capture of mesenchymal CTCs throughout disease progression,
which in turn could lend insight as to which patients might be at the most risk of false-negative CTC
analysis using the CellSearch® in the clinical setting. However, as previously mentioned, it has been
shown that depending on which size cassette the researcher chooses, recovery of CTCs from blood
samples varies significantly, which may be problematic for analysis of rare CTC populations [76]. It has
also been suggested that high contamination of leukocytes within captured CTC samples may provide
difficulties with molecular analysis of harvested cells [79].
6.2. Elucidating the Biology of CTCs and Metastasis via Preclinical Models
Overall, the studies described above provide useful technical guidelines for researchers to use
while planning preclinical metastasis studies and selecting the CTC technology that will best suit their
needs. While the described studies have provided an improved understanding of the biology of CTCs
and their relationship with metastatic disease, several other elegant studies (described below) have
also contributed valuable knowledge in this area.
A preclinical study conducted by Baccelli et al. (2013) [80] demonstrated that CTCs isolated from
breast cancer patient samples contained transplantable metastasis-initiating cells, which gave rise
to metastatic disease in mice. Co-expression of CD44v6 and MET was observed to be particularly
important for metastasis initiation where interaction with HGF in breast cancer metastases enhanced
MET-kinase signaling [80]. Another study by Vishnoi and colleagues (2015) [81] used patient
samples to culture CTC-derived 3D tumorspheres that allowed for the assessment of biomarker
profiling and biological characteristics. Using multiparametric flow cytometry, they revealed that
enriched CTC populations from breast tumors had unique gene signatures. They also observed that
FACS-sorted CTC populations, which expanded into 3D CTC tumorspheres in non-adherent stem
cell conditions, had suggestive metastatic competency and had cellular protrusions. Through their
findings, they elucidated mechanisms for the generation of tumor-associated vesicles (oncosomes) and
their related role in mediating intracellular signaling. Lastly, they were able to characterize the 3D CTC
tumorspheres as non-hematopoietic, tumorigenic, and as containing stem-cell properties [81]. In a
report from Zhang et al. (2013) [82], CTCs isolated from patients with breast cancer were characterized
and used to create multiple cell lines for subsequent in vivo and in vitro work. This study identified
a potential signature for breast cancer brain metastasis and analyzed these cells for invasiveness
and metastatic competency. With the development of brain metastatic breast cancer CTC cell lines,
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this group is now exploring potential protein signatures and mechanisms of brain cancer metastasis in
the preclinical setting [82]. Lastly, a review by Kang and Pantel (2013) [83] nicely summarizes how
animal models of CTCs mimic the complexity of patient cancers in the clinic and how preclinical
studies have identified many important mechanisms of metastasis including pathways, inhibitors,
and gene signatures that are accelerating the identification and implementation of clinically relevant
CTC information.
7. Conclusions and Future Directions
In summary, preclinical CTC analysis has provided insight into mechanisms of cancer metastasis,
into the transition between epithelial-to-mesenchymal phenotypes, and into potential new biomarkers.
Technological advances in single-cell analysis have also elucidated potential gene expression profiles
and cell mutations, which influence cell aggressiveness. Future work focused on CTCs will allow
researchers to continue to better understand the biology underlying the metastatic process and allows
for metastasis-specific drug development as well as assessment of therapy response. Preclinical studies
will continue to identify potential biomarkers, gene signatures, survival mechanisms, and novel
mechanisms of metastasis through CTC analysis. Single-cell genomic analysis of CTCs will provide
more insights into phenotypic changes, which may lead to disease progression and metastasis.
By converging preclinical and clinical CTC studies, there has already been great development in
the intellectual framework of the metastasis field, which has generated many unresolved questions to
be addressed in future studies to improve cancer therapies [82]. The accessibility of liquid biopsies such
as CTC assays will allow for continued focus on combined preclinical/clinical work by elucidating
mechanisms of cancer progression in patients’ own CTC samples. This targeted work will not only
benefit patients with metastatic cancer, but also patients with early-stage cancers who may be at high
risk for cancer progression.
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